73
Publications of the University of Eastern Finland Dissertations in Health Sciences dissertations Sini Pirnes-Karhu Spermidine/spermine N 1 -acetyltransferase in Mouse Hematopoiesis and Bone Remodeling and in Human Leukemias

Spermidine/spermine -acetyltransferase in Mouse ...epublications.uef.fi/pub/urn_isbn_978-952-61-1321-0/urn_isbn_978-952... · mononuclear cells of these patients was associated with

  • Upload
    others

  • View
    4

  • Download
    0

Embed Size (px)

Citation preview

Publications of the University of Eastern Finland

Dissertations in Health Sciences

isbn 978-952-61-1320-3

Publications of the University of Eastern FinlandDissertations in Health Sciences

Polyamines are ubiquitious

molecules essential for cell

proliferation. However, the

role of polyamine metabolism

in the immune response,

hematopoiesis, and bone

remodeling is largely unknown

and was thus addressed in this

study. The study showed that

enhanced activity of spermidine/

spermine N1-acetyltransferase

(SSAT), a catabolic regulator of

polyamines, was associated with

disturbed hematopoiesis and bone

remodeling in mice and myeloid

leukemias in humans.

dissertatio

ns | 207 | S

ini P

irn

es-Ka

rh

u | Sperm

idine/spermine N

1-acetyltransferase in Mouse H

ematopoiesis and B

one Rem

odeling...

Sini Pirnes-KarhuSpermidine/spermine

N1-acetyltransferase in Mouse Hematopoiesis

and Bone Remodeling and in Human Leukemias

Sini Pirnes-Karhu

Spermidine/spermine N1-acetyltransferase in Mouse Hematopoiesis and Bone Remodeling and in Human Leukemias

SINI PIRNES-KARHU

Spermidine/spermine N1-acetyltransferase

in Mouse Hematopoiesis and Bone

Remodeling and in Human Leukemias

To be presented by permission of the Faculty of Health Sciences, University of Eastern Finland for

public examination in Tietoteknia Auditorium (TTA), Kuopio,

on Saturday, December 14th 2013, at 1 pm

Publications of the University of Eastern Finland

Dissertations in Health Sciences

Number 207

Department of Biotechnology and Molecular Medicine

A.I.Virtanen Institute for Molecular Sciences

Faculty of Health Sciences

University of Eastern Finland

Tampere

2013

Juvenes Print – Suomen Yliopistopaino Oy

Tampere, 2013

Series Editors:

Professor Veli-Matti Kosma, M.D., Ph.D.

Institute of Clinical Medicine, Pathology

Faculty of Health Sciences

Professor Hannele Turunen, Ph.D.

Department of Nursing Science

Faculty of Health Sciences

Professor Olli Gröhn, Ph.D.

A.I. Virtanen Institute for Molecular Sciences

Faculty of Health Sciences

Professor Kai Kaarniranta, M.D., Ph.D.

Institute of Clinical Medicine, Ophthalmology

Faculty of Health Sciences

Lecturer Veli-Pekka Ranta, Ph.D. (pharmacy)

School of Pharmacy

Faculty of Health Sciences

Distributor:

University of Eastern Finland

Kuopio Campus Library

P.O.Box 1627

FI-70211 Kuopio, Finland

http://www.uef.fi/kirjasto

ISBN 978-952-61-1320-3 (print)

ISBN 978-952-61-1321-0 (pdf)

ISSN 1798-5706 (print)

ISSN 1798-5714 (pdf)

ISSN-L 1798-5706

III

Author’s address: Biotechnology and Molecular Medicine

A.I.Virtanen Institute

University of Eastern Finland

KUOPIO

FINLAND

e-mail: [email protected]

Supervisors: Professor Leena Alhonen, Ph.D.

A.I.Virtanen Istitute

University of Eastern Finland

KUOPIO

FINLAND

Anne Uimari, Ph.D.

A.I.Virtanen Institute

University of Eastern Finland

KUOPIO

FINLAND

Reviewers: Docent Jarmo Wahlfors, Ph.D.

Research Council for Health

Academy of Finland

HELSINKI

FINLAND

Docent Juhani Sand, Ph.D.

Division 2

Tampere University Hospital

TAMPERE

FINLAND

Opponent: Professor Leif C. Andersson, MD, Ph.D.

Haartman institute

University of Helsinki

HELSINKI

FINLAND

IV

V

Pirnes-Karhu, Sini. Spermidine/spermine N1-acetyltransferase in Mouse Hematopoiesis and Bone Remodeling and in

Human Leukemias. University of Eastern Finland, Faculty of Health Sciences

Publications of the University of Eastern Finland. Dissertations in Health Sciences 207. 2013. 56 p.

ISBN 978-952-61-1320-3 (print)

ISBN 978-952-61-1321-0 (pdf)

ISSN 1798-5706 (print)

ISSN 1798-5714 (pdf)

ISSN-L 1798-5706

ABSTRACT

Polyamines are ubiquitous molecules essential for cell proliferation. Induction of the

catabolic enzyme of polyamines, spermidine/spermine N1-acetyltransferase (SSAT), is

successfully used to limit cancer cell growth in cell culture. In animal models, however,

SSAT overexpression has been shown to increase susceptibility to cancer. In the present

study, the role of enhanced polyamine catabolism in homeostasis of hematopoietic and

bone systems were investigated in mice overexpressing SSAT (SSAT mice) and its

association to hematopoietic malignancies was studied with patient samples.

The basal levels of serum and hepatic inflammatory markers of SSAT mice were

comparable to those encountered in wild-type littermates. When exposed to endotoxin

SSAT mice displayed a slightly enhanced anti-inflammatory response but the survival and

symptoms of the SSAT mice were similar to those of wild-type mice. Further studies of cells

and tissues of the immune system revealed that the hematopoietic phenotype of SSAT mice

fulfilled the criteria of mouse myeloproliferative disease.

The myeloproliferation of SSAT mice resulted from both the intrinsic SSAT

overexpression of hematopoietic cells and microenvironmental factors. Characterization of

the bone phenotype of SSAT mice showed altered structure of bones of SSAT mice to

provide larger niche for hematopoietic cells. SSAT mice also showed cell-autonomously

impaired osteoblastogenesis and increased number of premature osteoblasts.

The association between SSAT activity and myeloproliferation was supported by

findings from human leukemia patients. The SSAT activity in peripheral blood

mononuclear cells of these patients was associated with the leukocyte number in myeloid

leukemias but not in lymphoid leukemia. Further investigation of SSAT mice provided

evidence that the association between SSAT and myeloproliferation might be mediated

through epigenetic factors.

Our results show that enhanced SSAT activity leads to aberrant bone formation and

subsequent changes in bone marrow microenvironment. In conjunction with enhanced

intrinsic SSAT activity of hematopoietic cells, this results in a myeloproliferative disease in

SSAT mice. The role of SSAT activity in myelopoiesis is further supported by the

association between SSAT activity and the white blood cell count in human myeloid

leukemias. National Library of Medicine Classification: QU 141, QU 475, WE 200, WH 140, WH 250, WH 380

Medical Subject Headings: Acetyltransferases/metabolism; Bone Marrow; Epigenesis, Genetic; Hematopoiesis;

Human; Leukemia, Myeloid; Mice; Myeloproliferative Disorders; Osteogenesis; Oxidative stress; Polyamines

VI

VII

Pirnes-Karhu Sini. Spermidiini/spermiini-N1-asetyylitransferaasi hiirten veren- ja luunmuodostuksessa sekä

ihmisten leukemioissa. Itä-Suomen yliopisto, Terveystieteiden tiedekunta

Publications of the University of Eastern Finland. Dissertations in Health Sciences 207. 2013. 56 s.

ISBN 978-952-61-1320-3 (print)

ISBN 978-952-61-1321-0 (pdf)

ISSN 1798-5706 (print)

ISSN 1798-5714 (pdf)

ISSN-L 1798-5706

TIIVISTELMÄ

Polyamiinit ovat solujen kasvulle välttämättömiä molekyylejä. Niitä hajottavan entsyymin,

spermidiini/spermiini-N1-asetyylitransferaasin (SSAT), indusointia on käytetty rajoittamaan

viljeltyjen syöpäsolujen kasvua. Eläinmalleissa puolestaan SSAT-geenin yli-ilmentäminen

on myös lisännyt alttiutta syövän synnylle. Tässä väitöskirjatutkimuksessa selvitettiin

kohonneen polyamiinikatabolian roolia veren- ja luunmuodostuksessa SSAT-geeniä yli-

ilmentävillä hiirillä (SSAT-hiiret) ja sen yhteyttä verisyöpiin potilasnäytteillä.

SSAT-hiirten seerumista ja maksasta mitattujen tulehdusmarkkereiden perustasot olivat

verrattavia villityypin hiirten markkereiden tasoon. SSAT-hiirten vaste endotoksiinille oli

kuitenkin lievästi tulehdusta hillitsevä. Tästä huolimatta eloonjääminen ja oireet olivat

verrattavia villityypin hiiren vastaaviin. Immunologisten solujen ja kudosten

lisätutkimukset osoittivat että SSAT-hiirten ilmiasu täytti hiirten myeloproliferatiivisen

sairauden kriteerit.

SSAT-hiirten myeloproliferatio syntyi yhdessä valkosolujen sisäisen SSAT:n yli-

ilmentämisen ja luuytimen mikroympäristön tekijöiden seurauksena. SSAT-hiirten luiden

lähempi tarkastelu osoitti niiden muuttuneen rakenteen muodostavan suuremman tilan

veren soluille. SSAT-hiirillä havaittiin lisäksi luuta muodostavien solujen (osteoblastien)

erilaistumisen olevan ympäristöstä riippumattomasti häiriintynyt ja epäkypsien

osteoblastien määrän kasvaneen.

SSAT-aktiivisuuden ja myeloproliferaation välillä havaittua yhteyttä vahvisti ihmisen

leukemianäytteiden tutkimus. Leukemiapotilaiden perifeerisen veren mononukleaaristen

valkosolujen SSAT-aktiivisuus oli yhteydessä valkosolumäärään myeloista mutta ei

lymfoista leukemiaa sairastavilla potilailla. Lisätutkimukset SSAT-hiirillä viittasivat

epigeneettisten tekijöiden olevan yhteydessä SSAT-geenin ja myeloproliferaation välillä

havaittuun suhteeseen.

Saamamme tulokset osoittavat kohonneen SSAT-aktiivisuuden johtavan epänormaaliin

luunmuodostukseen ja siitä johtuen poikkeavaan luuytimen mikroympäristöön. Yhdessä

veren solujen kohonneen sisäisen SSAT-aktiivisuuden kanssa tämä johtaa

myeloproliferatiivisen taudin kehittymiseen SSAT-hiirillä. SSAT-aktiivisuuden osuutta

myelopoieesissa tukee lisäksi havainto SSAT-aktiivisuuden yhteydestä valkosolumäärään

myeloista leukemiaa sairastavilla potilailla.

Yleinen Suomalainen asiasanasto: epigenetiikka; hiiret; ihmiset; immuunijärjestelmä; leukemia; luuydin;

luusto; polyamiinit; veri

VIII

IX

Acknowledgements

This work was carried out in the A.I.Virtanen Institute for Molecular Sciences, University of

Eastern Finland, during the years 2009‒2013.

I wish to express my sincere gratitude to my principal supervisor Professor Leena

Alhonen, PhD, who offered me an interesting project to work with and has shown belief in

my work ever since. My warm thanks belong also to my supervisor Anne Uimari, PhD, for

her inexhaustible guidance and all the stimulating discussions both in science and in

personal life. It has been great deal of fun to work with you!

I wish to thank Docent Jarmo Wahlfors, PhD, and Docent Juhani Sand, PhD, the official

reviewers of my thesis for their valuable comments to improve the manuscript. My thanks

belong also to Ewen Macdonald, PhD, and Sara Wojciechowski, B.Sc., who revised the

language of this manuscript.

I wish to express my gratitude to all our collaborators whose expertise in their own fields

has provided a strong foundation for my studies. I acknowledge Reijo Sironen, MD, PhD,

for his rigorous work with my first manuscript. I am very thankful for Docent Esa

Jantunen, MD, and Pentti Mäntymaa, MD, for their invaluable expertise in hematopoiesis

and hematopoietic malignancies as well as for Jorma Määttä, PhD, and Mikko Finnilä, MSc,

for their enthusiasm, work and advice with bone-related studies. I am grateful for Petri

Mäkinen, PhD, and Sara Wojciechowski for their kind and knowledgeable assistance with

flow cytometry. I wish to thank also Sohvi Hörkkö, MD, PhD, and Satu Mustjoki, MD, PhD,

for their scientific effort on my second and third manuscripts.

My warm thanks belong to all the present and former members of Leena’s laboratory

with whom I have had the pleasure to work. Thank you Tuomo Keinänen, PhD, Mervi

Hyvönen, PhD, Marko Pietilä, PhD, Taina Koponen, MSc, Marc Cerrada-Gimenez, PhD,

Eija Pirinen, PhD, Anita Lampinen, MSc, Tekele Fashe, MSc, Susanna Vuohelainen, MSc,

Maija Tusa, Lic.Phil., for helping me with my projects and making the working

environment so pleasant. I wish to direct my special thanks to the technical personnel who

participated in this study. Thank you, Anne Karppinen, Arja Korhonen, Marita Heikkinen,

Sisko Juutinen and Tuula Reponen, for your indefatigable and skillful help in the

laboratory and keeping the lab functional with all the practical essentials. In addition, I

would like to acknowledge Eeva Hakala, Jouko Mäkäräinen, Riitta Sinervirta, Helena Pernu

and all the personnel of National Laboratory Animal Center, especially Arja Konttinen,

Teija Oinonen and Virve Immonen, for efficiently managing the practical details.

My loving thanks belong to my family, especially to my husband Tero for making

everyday life so much fun. I also admire your calm response to stressful situations and I am

grateful for how you are able to make me calmer too. I am thankful for my parents, Maija

and Veijo, for encouraging me to pursue a quality education and follow my own path. I am

grateful for my beloved sisters Suvi, Säde and Sara and “brother” Teemu and my friends

both inside and outside of the scientific world, Ansku, Hanna-Maija and Eini, for sharing

the ups and downs of my work and personal life. I feel so privileged to have you all in my

life!

Lahti, November 2013

X

XI

List of the original publications

This dissertation is based on the following original publications:

I Pirnes-Karhu S, Sironen R, Alhonen L and Uimari A. Lipopolysaccharide-

induced anti-inflammatory acute phase response is enhanced in

spermidine/spermine N1-acetyltransferase (SSAT) overexpressing mice. Amino

Acids 42: 473-484, 2012.

II Pirnes-Karhu S, Mäntymaa P, Sironen R, Mäkinen PI, Wojciechowski S, Juutinen

S, Koistinaho J, Hörkkö S, Jantunen E, Alhonen L and Uimari A. Enhanced

polyamine catabolism disturbs hematopoietic lineage commitment and leads to a

myeloproliferative disease in mice overexpressing spermidine/spermine N1-

acetyltransferase. Amino Acids Epub Jul 9, 2013.

III Pirnes-Karhu S, Jantunen E, Mäntymaa P, Mustjoki S, Alhonen L and Uimari A.

Spermidine/spermine N1-acetyltransferase activity associates with white blood

cell count in myeloid leukemias. Manuscript.

IV Pirnes-Karhu S, Määttä J, Finnilä M, Alhonen L and Uimari A. Overexpression of

Spermidine/spermine N1-acetyltransferase Impairs Osteoblastogenesis and Alters

Mouse Bone Phenotype. Manuscript.

The following papers are referred to in the text by their Roman numeral.

The publications were adapted with the permission of the copyright owners.

XII

XIII

Contents

1 INTRODUCTION ...................................................................................................................... 1

2 REVIEW OF THE LITERATURE ............................................................................................. 3

2.1 POLYAMINE METABOLISM ............................................................................................................................ 3

2.1.1 Biosynthesis of polyamines............................................................................................................................. 4

2.1.1.1 Ornithine decarboxylase ......................................................................................................................... 4

2.1.1.2 S-adenosylmethionine decarboxylase................................................................................................... 5

2.1.1.3 Spermidine and spermine synthases .................................................................................................... 5

2.1.2 Polyamine catabolism ...................................................................................................................................... 5

2.1.2.1 Spermidine/spermine N1-acetyltransferase .......................................................................................... 6

2.1.2.2 Acetylpolyamine oxidase and spermine oxidase ................................................................................ 6

2.1.3 Polyamine transport ........................................................................................................................................ 7

2.1.4 Cellular functions of polyamines and SSAT ................................................................................................. 9

2.1.5 Polyamine catabolism in disease .................................................................................................................. 10

2.1.6 Polyamine metabolism in hematopoiesis ................................................................................................... 11

2.1.7 Polyamine metabolism in bone remodeling ............................................................................................... 11

2.2 HEMATOPOIESIS .............................................................................................................................................. 11

2.2.1 Hematopoietic stem cells .............................................................................................................................. 13

2.2.2 Maintenance of self-renewal capacity of hematopoietic stem cells ......................................................... 13

2.2.3 Lineage commitment of hematopoietic cells .............................................................................................. 14

2.2.4 Regulation of myeloid and megakaryocyte-erythroid lineage commitment ......................................... 16

2.2.5 Aging of the hematopoietic system ............................................................................................................. 16

2.2.6 Bone marrow microenvironment ................................................................................................................. 17

2.3 BONE STRUCTURE, FUNCTION AND DEVELOPMENT ......................................................................... 18

2.3.1 Bone remodeling ............................................................................................................................................ 18

2.3.2 Osteoblasts and bone formation................................................................................................................... 19

2.3.3 Osteoclasts and bone resorption .................................................................................................................. 20

3 AIMS OF THE STUDY ............................................................................................................ 21

4 MATERIALS AND METHODS ............................................................................................ 23

4.1 PATIENT SAMPLES .......................................................................................................................................... 23

4.2 MICE .................................................................................................................................................................... 23

4.3 ISOLATION OF BONE MARROW CELLS FROM MICE............................................................................. 23

4.4 EXPANSION OF FACS-SORTED LSK CELLS ............................................................................................... 24

4.5 DIFFERENTIATION OF MESENCHYMAL STROMAL CELLS TO OSTEOBLASTS .............................. 24

4.6 DIFFERENTIATION OF HEMATOPOIETIC CELLS TO OSTEOCLASTS ................................................ 24

4.7 STATISTICAL ANALYSES ............................................................................................................................... 24

4.8 ANALYTICAL METHODS ............................................................................................................................... 24

5 RESULTS .................................................................................................................................... 27

5.1 EFFECTS OF ACTIVATED POLYAMINE CATABOLISM IN IMMUNE RESPONSE (I) ........................ 27

5.2 EFFECTS OF ACTIVATED POLYAMINE CATABOLISM ON HEMATOPOISIS IN MICE (II) ............ 28

5.2.1 Polyamine cycle is enhanced in hematopoietic cells of SSAT mice ......................................................... 28

5.2.2 SSAT mice exhibit myeloproliferative phenotype ..................................................................................... 28

5.2.3 The myeloproliferative phenotype of SSAT mice results from both the intrinsic factors of bone

marrow cells and the bone marrow microenvironment ........................................................................................ 29

XIV

5.3 SSAT ACTIVITY IN MYELOID AND LYMPHOID LEUKEMIAS AND EPIGENETICS IN

HEMATOPOIETIC CELLS OF SSAT OVEREXPRESSING MICE (III) .................................................................... 29

5.3.1 Polyamine metabolism of human leukemic blood cells is disturbed ...................................................... 29

5.3.2 SSAT mice show epigenetic changes in hematopoietic cells and differential response to drugs

affecting epigenetic factors......................................................................................................................................... 29

5.4 EFFECTS OF ACTIVATED POLYAMINE CATABOLISM ON BONE REMODELING (IV) .................. 30

5.4.1 Polyamine metabolism of osteoblasts and osteoclasts is disturbed ........................................................ 30

5.4.2 SSAT overexpression affects osteoblastogenesis but not osteoclastogenesis cell-autonomously ....... 30

5.4.3 Induction of SSAT with α-methylspermidine disturbs wild-type osteoblastogenesis ......................... 31

5.4.4 Bone phenotype of SSAT mice reveals striking changes .......................................................................... 31

6 DISCUSSION ............................................................................................................................ 33

7 SUMMARY AND CONCLUSIONS ..................................................................................... 39

8 REFERENCES ............................................................................................................................ 41

ORIGINAL PUBLICATIONS I─IV .............................................................................................. 57

XV

Abbreviations

AdoMet S-adenosylmethionine

AGP alpha-1-acid glycoprotein

ALAT alanine aminotransferase

ALL acute lymphoid leukemia

ALP alkaline phosphatase

AML acute myeloid leukemia

APAO acetylpolyamine oxidase

AZ antizyme

AZI antizyme inhibitor

BMD bone mass density

B.Pm bone perimeter

BSP bone sialoprotein

BV bone volume

C/EBP CCAAT-enhancer-binding

protein

CLP common lymphoid

progenitor

CML chronic myeloid leukemia

CMP common myeloid progenitors

CRP C-reactive protein

Cs.Th cross-sectional thickness

CTSK cathepsin K

CTX carboxy-terminal cross-

linking telopeptide

dcAdoMet decarboxylated S-

adenosylmethionine

DFMO difluoromethylornithine

DNMT DNA methyltransferases

GM-CSF granulocyte-macrophage

colony-stimulating factor

GMP granulocyte-macrophage

progenitors

HAT histone acetyltransferase

HDAC histone deacetylase

HMT histone methyltransferase

HSC hematopoietic stem cell

IL-1β interleukin-1beta

IL-6 interleukin-6

IL-10 interleukin-10

INF-γ interferon gamma

LMPP lymphoid-primed

multipotent progenitor

LPS lipopolysaccharide

LSK lineage-negative Sca-1+ c-Kit+

cells

LT-HSC long-term hematopoietic stem

cell

MEP megakaryocyte-erythrocyte

progenitors

MPP multipotent progenitor

MSC mesenchymal stromal cell

MTA 5’-deoxy-5’-

methylthioadenosine

MT-SSAT spermidine/spermine N1-

acetyltransferase under

metallothionein promoter

XVI

NFATc1 nuclear factor of activated T-

cells cytoplasmic 1

NF-κB nuclear factor kappa-B

OC osteocalcin

ODC ornithine decarboxylase

OPN osteopontin

OSX osterix

PBMC peripheral blood

mononuclear cell

PINP procollagen type I propeptide

Po.V total volume of porosity

RUNX2 runt-related transcription

factor 2

ROS reactive oxygen species

SAA serum amyloid A

SAMDC S-adenosylmethionine

decarboxylase

SCF stem cell factor

SMI structural model index

SMO spermine oxidase

SRS Snyder-Robinson syndrome

SSAT spermidine/spermine N1-

acetyltransferase

SSATKO spermidine/spermine N1-

acetyltransferase knockout

ST-HSC short-term hematopoietic

stem cell

Tb.Th trabecular thickness

Tb.N trabecular number

TNF-α tumor necrosis factor alpha

TPO thrombopoietin

TRAcP tartrate-resistant acid

phosphatase

TV tissue volume

WBC white blood cell

1 Introduction

Cancers in general result from disturbances of several normal cellular functions at the same

time. Tissue homeostasis is disrupted also during the normal aging process due to

alterations occurring at the molecular level and these changes can predispose to cancer

development. In addition to cell-autonomous factors, the surrounding stroma may

contribute to the malignancy of neoplasias. Thus, elucidation of the function of factors

predisposing to cancer represents one way to prevent cancer development.

All blood cells, including platelets, red blood cells and white blood cells, are derived

from multi-potent hematopoietic stem cells. Platelets, which originate from

megakaryocytes, are involved in blood coagulation process whereas the function of red

blood cells is to bind oxygen and deliver it to tissues. White blood cells, further subdivided

into myeloid and lymphoid lineages, are responsible for the immune defense of body. In

the hematopoietic system the disruption of tissue homeostasis with aging leads not only to

an increased propensity to anemia but also to the attenuation of lymphoid lineage and

further to dominance by myeloid lineages (Woolthuis et al. 2011). The domination of

myeloid lineages is connected to the increased incidence of myeloid leukemias observed in

the elderly. In addition to cell-intrinsic factors, recently much attention has been focused on

the role of the micro-environment in the development of hematological malignancies

(Askmyr et al. 2011; Carlesso and Cardoso 2010).

Bone is a connective tissue consisting of cellular components as well as of an organic and

inorganic matrix. Osteoblasts, osteoclasts and osteocytes are the cellular components of

bone. Bone serves a variety of functions e.g. providing structural support and protection for

internal organs as well as a suitable environment where hematopoiesis can take place. Bone

is constantly being renewed by a process termed remodeling (Eriksen 2010; Kular et al.

2012). This is carried out by bone-resorbing osteoclasts and bone-forming osteoblasts. The

osteoclasts break down the old or damaged bone and osteoblasts re-fill the gap in the bone

matrix. In healthy young bone the process of bone resorption and bone formation are

tightly coupled to maintain homeostasis and overall bone mass. Thus, a defect in either of

the events can evoke an imbalance in bone structure, leading to a disease state.

Polyamines are small cationic molecules which have been conserved during the course

of evolution. Due to their cationic nature, polyamines interact with negatively charged

macromolecules (Igarashi and Kashiwagi 2010; Watanabe et al. 1991). Through these

interactions, polyamines are involved in many cellular functions, with the best known

being their function in cell proliferation. Polyamines have been linked also to neoplastic

growth as biosynthesis of polyamines is enhanced in cancer cells as compared to healthy

tissue (Wallace et al. 2003). In cell cultures, the induction of the activity of the catabolic

enzyme of polyamines, spermidine/spermine N1-acetyltransferase (SSAT), has been

successfully used to limit cancer cell growth (Kee et al. 2004b; Vujcic et al. 2000). In animal

models, however, also opposite results are found; SSAT overexpression has been reported

to enhance the animal’s susceptibility to skin and intestinal cancer (Coleman et al. 2002;

2

Tucker et al. 2005). Additionally, human breast cancer patients have been shown to exhibit

increased SSAT activity in their tumor cells compared to healthy tissue (Wallace et al. 2000).

This study aimed to reveal the role of disturbed polyamine metabolism in tissue

homeostasis of the hematopoietic system. Thereby, polyamine levels and activity of their

metabolic enzymes were measured from leukemia patient samples. Furthermore, the

immunological and hematopoietic phenotypes of SSAT overexpressing mice were

examined. These mice were shown to develop a myeloproliferative disease with the bone

marrow microenvironment partly contributing to its development. Thus, in order to clarify

how the microenvironmental factors could affect hematopoiesis the bone remodeling status

of SSAT mice were also characterized.

3

2 Review of the literature

2.1 POLYAMINE METABOLISM

Polyamines are amino acid-derived aliphatic molecules found in all eukaryotes and nearly

all prokaryotes (Cohen 1998). The three polyamines present in mammalian cells, putrescine,

spermidine and spermine, contain two to four amino groups and at physiological pH they

are fully protonated and possess cationic characteristics (Figure 1). Unlike the divalent

inorganic cations, like Ca2+, the positive charge in polyamines is distributed along the

carbon backbone. Thus, polyamines bind readily to negatively charged macromolecules

such as DNA, RNA and proteins and therefore the proportion of free cellular polyamines is

small (Igarashi and Kashiwagi 2010; Watanabe et al. 1991). Spermidine and spermine

interact more strongly with macromolecules than putrescine. The ratio of spermidine and

spermine is claimed to be important for cellular functions (Pegg and Michael 2010). The

cellular content of spermine equals or exceeds that of spermidine only in animal tissues

whereas not all prokaryotic species contain spermine at all. Putrescine is often considered

as the precursor molecule and spermine as a reservoir molecule for spermidine. However,

both of these molecules have been shown to possess their own individual functions.

In view of their ability to form ionic bonds with other molecules and, additionally, to

serve as precursors for other molecules, polyamines are involved in many cellular

functions, such as transcription, translation and cell signaling. As a result of their important

role in these functions, it is recognized that polyamines are essential for normal cell growth

and development of organisms (Nishimura et al. 2002; Pendeville et al. 2001). The cellular

polyamine content and the activity of their biosynthetic enzymes increase rapidly when

proliferation is induced (Wallace 2009). The depletion of the cellular polyamine content

triggers growth arrest by reducing synthesis of nucleic acids and proteins whereas high

concentrations of polyamines may be toxic to cells (Davis et al. 1992; Persson 2009). For this

reason, cellular concentrations of polyamines are very tightly regulated. In addition to their

requirement in cell proliferation, the conservation of polyamines across evolution is also

evidence emphasizing biological significance of these molecules (Wallace et al. 2003).

4

Figure 1 Mammalian polyamines, putrescine, spermidine and spermine. Polyamines are small

aliphatic molecules with two to four cationic amino groups. Positively charged amino groups

enable interaction with negatively charged macromolecules such as DNA and RNA.

2.1.1 Biosynthesis of polyamines

The major source of polyamines in mammals is via de novo biosynthesis, whereas dietary

polyamines and polyamine production by gut microflora make a smaller contribution

(Wallace 2009). The biosynthesis of polyamines uses two amino acids, methionine and

arginine, as precursors (Cohen 1998). Methionine is converted to S-adenosylmethionine

(AdoMet) and L-arginine to L-ornithine and both are then further decarboxylated by S-

adenosylmethionine decarboxylase (SAMDC) and ornithine decarboxylase (ODC),

respectively. The decarboxylation of L-ornithine results in the formation of the diamine

putrescine. Spermidine is synthesized from putrescine, and spermine further from

spermidine, by transfer of aminopropyl group which is provided by decarboxylated S-

adenosylmethionine. The enzymes which catalyze the transfer are spermidine synthase and

spermine synthase. The metabolic pathway of polyamines is presented in Figure 2.

2.1.1.1 Ornithine decarboxylase

Ornithine decarboxylase (ODC) is a pyridoxal phosphate -dependent enzyme which

catalyzes the decarboxylation of L-ornithine to form the diamine putrescine. ODC is one of

the two rate-limiting enzymes of polyamine biosynthesis. The knockout of the gene and

subsequent loss of intracellular polyamine pools is lethal in mice (Pendeville et al. 2001).

ODC functions as a homodimer with two active sites (Coleman et al. 1994). The association

between the two ODC subunits is relatively weak and the dimers exist in rapid equilibrium

with the inactive monomers. ODC has a very rapid turnover rate for a mammalian enzyme.

The depletion of cellular polyamine pools stabilizes the enzyme whereas in excess of

polyamines ODC is directed to degradation. The degradation is brought about by 26S

proteasome but instead of ubiquitination ODC associates with protein termed antizyme

(AZ) that directs it to proteosomal degradation. AZ is synthesized and its degradation is

5

inhibited in response to an increase in cellular polyamine content. It binds the ODC

monomer preventing formation of dimer and, thus, it inhibits enzymatic activity. On the

other hand, AZ activity is regulated by antizyme inhibitor (AZI) which binds AZ more

tightly than ODC and thereby releases ODC from ODC-AZ complex (Murakami et al.

1996). ODC protein levels are controlled also by high cellular polyamine content through

translational regulation.

2.1.1.2 S-adenosylmethionine decarboxylase

The second rate-limiting enzyme of biosynthesis of polyamines is S-adenosylmethionine

decarboxylase (SAMDC) (Nishimura et al. 2002). Inactivation of mouse SAMDC gene and

the subsequent loss of intracellular polyamine pools is lethal at early stage of development.

SAMDC is synthesized as proenzyme which after intramolecular cleavage reactions forms

α and β subunits (Pegg 2009). In mammals, SAMDC functions as a tetramer of two pairs of

α and β subunits and, additionally, it contains a covalently bound prosthetic group,

pyruvate. SAMDC catalyzes the decarboxylation of AdoMet producing an aminopropyl

donor for synthesis of higher polyamines (Pegg et al. 1998). Decarboxylated AdoMet

(dcAdoMet) is required in polyamine biosynthesis whereas the non-decarboxylated form of

AdoMet is needed as a methyl group donor in methyl transfer reactions. The

decarboxylated form is not suitable for this purpose. For this reason, the steady-state level

of dcAdoMet is kept very low and SAMDC activity is highly regulated by polyamines at

the transcriptional, translational and protein levels. Putrescine enhances the proenzyme

processing and catalytic activity of SAMDC whereas high concentrations of spermidine and

spermine suppress transcription and translation and accelerate turn-over rate of SAMDC

(Kameji and Pegg 1987; Pegg 2009). SAMDC is degraded by 26S proteasome after

polyubiquitination.

2.1.1.3 Spermidine and spermine synthases

Spermidine and spermine synthases are aminopropyl transferases that function as

homodimers and use dcAdoMet as a donor of aminopropyl group (Ikeguchi et al. 2006;

Pegg and Michael 2010; Wu et al. 2007). Mammalian aminopropyltransferases are highly

specific for their acceptor molecules, putrescine and spermidine, from which spermidine

and spermine are formed, respectively. The by-product of the process, 5’-deoxy-5’-

methylthioadenosine (MTA), strongly inhibits both spermidine and spermine synthase

(Ikeguchi et al. 2006; Wu et al. 2008). However, MTA is normally rapidly degraded to

adenosine and methionine and, thus, does not have a great inhibitory effect in vivo.

Spermidine and spermine synthases are expressed constitutively and, unlike ODC and

SAMDC, not readily induced (Ikeguchi et al. 2006; Pegg and Michael 2010). Rather their

enzymatic activity is limited by the availability of their common substrate, dcAdoMet.

2.1.2 Polyamine catabolism

Spermine is converted to spermidine and spermidine to putrescine by the concerted action

of two enzymes, spermidine/spermine N1-acetyltransferase (SSAT) and acetylpolyamine

oxidase (APAO) (Casero and Pegg 1993). SSAT adds acetyl groups to aminopropyl end(s)

of spermidine and spermine. The acetylated forms are then either exported or oxidized by

APAO which cleaves the molecules to generate N-acetylaminopropanal and the smaller

polyamine. Additionally, spermine can be converted directly to spermidine by spermine

6

oxidase (SMO) (Vujcic et al. 2002). Due to its ability to directly convert spermine to

spermidine, SMO can be considered as a way to recycle the higher polyamines (Wallace

2009). The spermidine/spermine N1-acetyltransferase (SSAT) pathway, on the other hand,

can be considered to be mainly utilized for depletion of the polyamines as

acetylpolyamines produced by SSAT are readily excreted. For this reason, acetylpolyamines

are only rarely found in normal cells, however, these molecules can be found in high

concentrations in cancer cells (Kingsnorth and Wallace 1985). Furthermore, acetylation of

polyamines reduces their charge and thus decreases their functional ability and potency to

bind anionic molecules.

High levels of SSAT have been shown to increase polyamine flux (Janne et al. 2006; Kee

et al. 2004b). The activity of SSAT decreases polyamine levels and to compensate the

polyamine depletion ODC and SAMDC are induced. The increased flux increases

consumption of ATP and acetyl-CoA in addition to increased production of toxic

compounds such as H2O2.

2.1.2.1 Spermidine/spermine N1-acetyltransferase

Spermidine/spermine N1-acetyltransferase is considered as a key catabolic enzyme of

polyamines (Pegg 2008). SSAT is a part of the GCN5-related N-acetyltransferase (GNAT)

family. It is primarily a cytosolic enzyme, although there is evidence of its localization in

mitochondria and nucleus as well (Holst et al. 2008; Uimari et al. 2009). SSAT is active as a

homodimer. Using acetyl-CoA as a donor for acetyl group SSAT is able to acetylate N1-

position of spermidine and either end of spermine as spermine is a symmetrical molecule

(Matsui and Pegg 1981). In addition, other molecules with the aminopropyl structure are

excellent substrates for SSAT, whereas for example, putrescine with its aminobutyl group

does not (Della Ragione and Pegg 1983).

SSAT is stringently regulated by polyamines and other factors at many levels, e.g.

transcription, mRNA processing, translation and protein stability (Casero and Pegg 2009;

Pegg 2008). Polyamine analogues, several molecules (growth factors, toxic compounds,

drugs) and various pathophysiological stimuli affect SSAT either directly or indirectly

through the regulation of polyamine levels. In the presence of high levels of polyamines,

transcription and translation of SSAT are increased whereas degradation of the protein and

incorrect splicing of the mRNA are reduced (Pegg 2008). Cellular SSAT activity is very low

under resting conditions but it can be readily induced by several factors and the stability of

the otherwise short-lived protein can be enhanced (Matsui and Pegg 1981; Persson and

Pegg 1984). When polyamines and polyamine analogues bind the SSAT protein, its half-life

is greatly prolonged since this prevents the ubiquitination and subsequent degradation by

the 26S proteasome (Coleman and Pegg 1997). Many polyamine analogs have strong effects

on the regulation of SSAT and as they are not substrates for SSAT, their content is not

reduced in response to its induction (Pegg 2008).

2.1.2.2 Acetylpolyamine oxidase and spermine oxidase

APAO is a peroxisomal FAD-dependent enzyme in the polyamine catabolic pathway

catalyzing the turn-over of N1-acetylated polyamines back to spermidine or putrescine

(Casero and Pegg 2009). Spermine can be converted back to spermidine also directly,

without the acetylation step, through the action of SMO (Vujcic et al. 2002). Both reactions,

oxidation by APAO or SMO, produce highly toxic by-products, hydrogen peroxide (H2O2)

7

and 3-acetoamidopropanal or 3-aminopropanal, respectively. APAO is located in

peroxisomes and this means that any oxidizing compounds produced by APAO activity

may be immediately detoxified by peroxisomal catalase. SMO, however, is located in the

cytosol and nucleus. Thus, the reactive oxygen species (ROS) produced by its activity can

be potentially more harmful to the cell (Murray-Stewart et al. 2008). APAO is constitutively

expressed and its activity is limited by the availability of its substrates, the acetylated forms

of polyamines, which are produced by action of SSAT (Holtta 1977; Vujcic et al. 2003).

APAO has very poor ability to oxidize non-acetylated polyamines. SMO, on the other hand,

is highly inducible and all of the analogues inducing SSAT also induce SMO expression

(Casero and Pegg 2009). APAO activity has been shown to be low in breast cancer patients

in comparison to healthy controls, thus partly contributing to the accumulation of cellular

acetylated polyamines (Kingsnorth and Wallace 1985; Wallace et al. 2000).

2.1.3 Polyamine transport

In addition to biosynthesis and catabolism, polyamine uptake and export are important

pathways in the regulation of intracellular polyamine content. If polyamine synthesis is

prevented, then the transport system becomes critical for normal cellular growth. The

polyamine transporters have been well documented in prokaryotes but the transport

mechanisms in mammalian cells are not well characterized and no mammalian transporter

genes have been cloned yet. Food contains large quantities of polyamines which are

absorbed from the intestine and can be transported for use by cells throughout the body

(Bardocz 1993). Additionally intestinal bacteria produce and excrete polyamines which can

be taken up and utilized (Wallace et al. 2003). Due to the positive charge of polyamines,

they require a transport system to permit exogenous uptake. Thus, cells take up polyamines

from the environment through an active, energy-requiring, transport system (Seiler et al.

1996). Two transport systems for uptake of polyamines have been recognized: a sodium-

dependent form that has a preference for putrescine (although it can transport also

spermidine and spermine) and a sodium-independent form that is capable of transporting

spermidine and spermine. Additionally, there has been postulated to be an endocytosis-

mediated mechanism for polyamine transport (Soulet et al. 2002).

The uptake and export of polyamines seem to be mediated by different transporters

since polyamine uptake-deficient mutant cells are able to excrete polyamines (Hyvonen et

al. 1994). However, both systems are regulated by the same factor, AZ, which also functions

as an ODC inhibitor (Sakata et al. 2000). The main polyamines to be exported are putrescine

and acetylated polyamines (Seiler et al. 1996). Acetylated polyamines do not function as

substrates for the polyamine uptake system and thus once exported, they are not

reaccumulated into cells (Byers and Pegg 1989). Exported acetylpolyamines are transported

to the kidneys and excreted in urine. In many cancers, it is known that there are elevated

urinary acetylpolyamine levels (Seiler et al. 1981).

8

Figure 2 Mammalian polyamine metabolism. Polyamine synthesis uses amino acids as

precursors. The polyamine metabolism can be considered as a cycle (red arrows). The higher

polyamines are produced from the smaller forms (spermidine from putrescine and spermine

from spermidine) by the action of biosynthetic enzymes, ODC, SAMDC, SPDSy, SPMSy, and can

again be converted back to the smaller forms by catabolic enzymes SMO, SSAT, APAO. The

polyamine cycle consumes metabolites such as Ac-Co and ATP and produces toxic compounds

(ROS and reactive aldehydes). Ac-coA, acetyl-coenzyme A; APAO, acetylpolyamineoxidase;

ARG, arginine; ATP, adenosine triphosphate; AZ, antizyme; dcAdoMet, decarboxylated S-

adenosylmethionine; MAT, methionine adenosyltransferase; MTA, methylthioadenosine; ODC,

ornithine decarboxylase; ROS, reactive oxygen species; S-AdoMet, S-adenosylmethionine;

SAMDC, S-adenosylmethionine decarboxylase; SMO, spermine oxidase; SPDSy, spermidine

synthase; SPMSy, spermine synthase; SSAT, spermidine/spermine N1-acetyltransferase

9

2.1.4 Cellular functions of polyamines and SSAT

Polyamines can stabilize DNA and protect it from damage that is caused by for example

oxidation and radiation (Ha et al. 1998b; Newton et al. 1996; TABOR 1962). Additionally,

among the polyamines, spermine has been reputed to exert protective roles also during

inflammation as it inhibits post-transcriptionally pro-inflammatory cytokine production in

human mononuclear cells (Ha et al. 1998a; Zhang et al. 1997b). Moreover, spermine has

been shown to reduce carrageenan-induced edema and partially protect from cecal ligation

and puncture -induced sepsis in mice (Zhang et al. 1997b; Zhu et al. 2009). Polyamines

modify gene activation and gene silencing by modulating the transition of DNA from the B-

to the Z-conformation, inducing chromosome condensation by neutralizing the charges on

histone and chromatin phosphate and by regulating activity of the histone

acetyltransferases (Fredericq et al. 1991; Hougaard et al. 1987; Thomas and Messner 1986).

Polyamines are known to be able to influence protein synthesis at various stages by

changing the structure of mRNA, tRNA and rRNA [reviewed in (Igarashi and Kashiwagi

2010)]. Furthermore, polyamines can change protein conformation by undergoing

interactions with acidic protein structures thereby disturbing their functions. Polyamines

regulate also membrane potential of cells by interacting with glutamate receptors and ion

channels (Donevan and Rogawski 1995; Williams 1997).

The best recognized function of polyamines is their role in cell proliferation. Similar to

the content of known cell cycle regulators, cyclins and cyclin-dependent kinases, also

polyamine concentration and activities of polyamine metabolic enzymes fluctuate during

the cell cycle (Oredsson 2003). The activity of ODC, and subsequently the polyamine levels,

peak at G1 and G2 phases whereas AZ and SSAT expressions are up-regulated during the

G2/M phase. The dramatic changes in putrescine concentration during cell cycle suggest

that this divalent polyamine directly drives cells through G1 restriction point to S phase

(Bettuzzi et al. 1999). Additionally, a specific role of spermidine in eukaryotic cell

proliferation is its posttranscriptional protein modification function in the formation of

eukaryotic elongation factor 5A, eIF5A. Spermidine serves as the sole precursor of

hypusine, a rare amino acid, which is required in the maturation of eIF5A (Park et al. 1981).

The maturation of eIF5A is prevented not only by depleted spermidine pools but also by

accumulated putrescine (Tome et al. 1997). Polyamines have a bivalent role in the

regulation of cellular functions as, in addition to cell proliferation, they can regulate also

apoptosis. The studies covering their role in inducing apoptosis are, however,

contradictory. The depletion of polyamines has been shown to both induce and prevent

apoptosis (Schipper et al. 2000). One can conclude from these studies that it is essential for

cell survival to maintain cellular polyamine content within a narrow range.

In addition to its central role in polyamine catabolism, the SSAT enzyme also possess

other functions. SSAT is known to autoacetylate its own lysine residue (Bewley et al. 2006).

Furthermore, SSAT can acetylate the deoxyhypusine/hypusine residue of eIF5A and,

thereby, regulate its activity (Lee et al. 2011). It is possible that also other molecules function

as substrates for SSAT. A recent study revealed SSAT to have an additional role in

repression of expression of other proteins, however, the repression was restricted to

exogenous proteins and only transiently transfected SSAT was able to exert any effects (Lee

et al. 2010). The mechanism, however, is not yet known but the effect of SSAT action does

not seem to depend on acetylpolyamines or on the depletion of polyamines. In addition,

SSAT activity and the concomitant depletion of local polyamines is believed to induce

10

inward rectifier potassium channel Kir4.2 (Chen et al. 2004; deHart et al. 2008).

Furthermore, SSAT binds α9β1 integrin and increased SSAT activity enhances cell

migration through colocalization of α9β1 integrin and Kir4.2 (Chen et al. 2004).

Furthermore, SSAT is linked to inflammatory responses through tumor-necrosis factor-α

(TNF-α) and non-steroidal anti-inflammatory drugs (NSAIDs) which are able to induce

SSAT activity (Babbar et al. 2007). Activation of SSAT will lead to polyamine depletion and

hence to a reduction in cell growth and triggering of apoptosis. This may be beneficial in

conditions of inflammatory stress.

2.1.5 Polyamine catabolism in disease

Studies of transgenic animals overexpressing or deficient for SSAT have pointed to a role

for SSAT in many disease states where the effects of disturbed polyamine metabolism are

mediated differently depending on the diseased tissue. A rapid depletion of spermidine

and spermine increases the susceptibility to pancreatitis (Alhonen et al. 2000; Hyvonen et

al. 2007). The accumulation of putrescine in hair follicles has evoked hair loss and skin

problems in SSAT overexpressing mice (Pietila et al. 1997; Pietila et al. 2001). A similar

polyamine profile and skin changes has been reported also in a patient with keratosis

follicularis spinulosa decalvans (KSFD) (Gimelli et al. 2002). A lower consumption of acetyl-

CoA as a result of reduced SSAT enzyme activity has caused insulin resistance in SSAT

knockout mice (Jell et al. 2007; Niiranen et al. 2006) whereas SSAT overexpressing mice

exhibited an increased consumption of acetyl-CoA and ATP and, thus, they represented

the opposite phenotype (Pirinen et al. 2007). Increased production of ROS as a consequence

of increased polyamine catabolism has been implicated in pathogenesis of

ischemia/reperfusion injury in stroke and acute renal tubular necrosis (Tomitori et al. 2005;

Zahedi et al. 2010).

Since polyamines display such a strong positive correlation with cell growth, it is not

surprising that the growth rate of cancer cells is also closely linked to the polyamine content

of the cell. An increase in ODC activity and the subsequent increase in cellular polyamine

pools have been considered to be an early event in several cancer cell types (Kingsnorth et

al. 1984a; Kingsnorth et al. 1984b). It might be anticipated that inhibition of biosynthesis or

enhancing the catabolism of polyamines would impair neoplastic growth. Decreased tumor

incidence was indeed found in a tumorigenesis initiation study with mice overexpressing

SSAT (Pietila et al. 2001). Furthermore, crossbreeding SSAT overexpressing mice with

TRAMP mice, which develop prostate tumors reduced the incidence of tumors (Kee et al.

2004a). However, SSAT overexpression has been linked also to increased susceptibility to

tumor growth. The tumor cells of breast cancer patients have increased SSAT activity and

decreased APAO activity in comparison to normal tissue (Wallace et al. 2000). The mouse

model of K6/SSAT mice overexpressing SSAT only in skin exhibited increased tumor

incidence in response to a two-stage tumorigenesis initiation protocol (Coleman et al. 2002).

In a study where APCmin mice were crossed with SSAT overexpressing mice, the SSAT

overexpression was associated with a susceptibility towards intestinal tumor growth

(Tucker et al. 2005). However, in such a situation the effect of SSAT seemed to be indirect

since prolonged exposure of intestine to increased levels of bile acid is known to predispose

to carcinogenesis (Reddy et al. 1977) and the SSAT mice have been shown to suffer from an

increased excretion of bile acids (Pirinen et al. 2010).

11

2.1.6 Polyamine metabolism in hematopoiesis

In addition to other neoplasias , polyamine metabolism has also been linked to leukemias.

The erythrocyte spermine content has prognostic value in childhood acute lymphoid

leukemia (ALL) (Bergeron et al. 1997). In addition, the ODC activity in peripheral blood

mononuclear cells from common myeloid leukemia (CML) patients has been shown to

reflect the neoplastic proliferation activity of leukemic cells (Tripathi et al. 2002).

Furthermore, the catabolic side of polyamine metabolism has been implicated in leukemias

since SSAT is differentially expressed during different stages of CML pointing to an

involvement of SSAT in disease transformation (Janssen et al. 2005). Additionally, SSAT

expression is increased in the transition phase of acute megakaryoblastic leukemia (AMKL),

a form of acute myeloid leukemia, common in individuals with Down syndrome (Lightfoot

et al. 2004). Furthermore, SSAT is super-induced in response to treatment with 12-0-

tetradecanoylphorbol-13-acetate (TPA), a compound which triggers the differentiation of

human myeloblastic leukemia cell line ML-1. Thus, SSAT was speculated to be an

important regulator of myeloid differentiation (Wang et al. 1998).

2.1.7 Polyamine metabolism in bone remodeling

There are a few experiments describing the role of polyamines in bone formation (Tjabringa

et al. 2008) and bone resorption (Yamamoto et al. 2012). Tjabringa et al (2008) showed that

addition of spermine could enhance osteoblastogenesis in cultured mesenchymal stromal

cells (MSC). Yamamoto et al. (2012) found spermidine or spermine treatment to prevent

bone loss in ovariectomized mice. The effect of administered polyamines was mediated

through disruption of osteoclast maturation. Polyamines did not have any substantial effect

on osteoblasts in that study. Polyamine metabolism has been lined to bone homeostasis also

in a human disorder called Snyder-Robinson syndrome (SRS) which is associated with

mutations in the spermine synthase gene (Becerra-Solano et al. 2009; Cason et al. 2003; de

Alencastro et al. 2008). SRS patients were reported to suffer from osteoporosis and the

authors claimed that it resembled osteogenesis imperfecta, although, the diagnosis was not

confirmed (Arena et al. 1996; Becerra-Solano et al. 2009; de Alencastro et al. 2008). SRS

patients exhibit only a modest reduction in spermine but their spermidine content is greatly

elevated (Cason et al. 2003). Thus, the spermine:spermidine ratio is reduced and the total

polyamine content increased with the putrescine level being decreased. Additionally, mice

lacking spermine synthase activity, termed gyro (Gy) mice, have been described to have a

similar cellular spermine:spermidine ratio as SRS patients and also to suffer a defect in bone

development in addition to other symptoms (Lyon et al. 1986; Mackintosh and Pegg 2000;

Meyer et al. 1998). However, Gy mice have a deletion of a part of the X chromosome that

inactivates not only the spermine synthase gene but also Phex, a gene that regulates

phosphate metabolism. Therefore, caution is necessary in the use of Gy mice to study the

role of spermine in bone formation (Wang et al. 2004).

2.2 HEMATOPOIESIS

Hematopoietic stem cells (HSC), like all other multi-potent stem cells in the body, are able

to both self-renew and differentiate into more mature cells. Self-renewal is essential for

maintaining the HSC compartment and hence is a prerequisite for lifelong hematopoiesis.

HSC divisions can be either symmetrical or asymmetrical (Blank et al. 2008). During

12

symmetrical cell division, both daughter cells retain stem cell properties whereas in

asymmetrical cell division one of the resulting daughter cells maintains stem cell properties

but the other commits to a more differentiated outcome. As a result of symmetrical cell

division, the stem cell pool is expanded. On the other hand, asymmetrical cell division

maintains the HSC compartment. The more differentiated progeny progressively lose their

self-renewal potential and become more restricted in their differentiation capacity. All

circulating blood cells, including platelets, red blood cells and white blood cells, are

descendants of multi-potent hematopoietic stem cells. Platelets (also called thrombocytes)

are important participants in the blood coagulation process. They are derived by budding

from large precursors called megakaryocytes. Red blood cells, or erythrocytes, bind oxygen

and deliver it to tissues. During differentiation erythrocytes undergo denucleation in order

to gain space for hemoglobin, the molecule able used for binding and transporting oxygen.

White blood cells, also called leukocytes, are responsible for the immune defense in the

body. They are further subdivided into myeloid and lymphoid lineages which both have

several subpopulations with different specialized tasks in immune defense. The

commitment of hematopoietic lineages is presented in Figure 3.

Figure 3 Origin of hematopoietic and bone cells. Hematopoietic and bone cells both originate

from the bone marrow. All the mature hematopoietic cells (right side of figure) develop from

myeloid and lymphoid progenitors that differentiated from the hematopoietic stem cells. The

bone destructing osteoclasts also have a hematopoietic origin whereas the bone forming

osteoblasts derive from the mesenchymal stromal cells. CLP, common lymphoid progenitor;

CMP, common myeloid progenitor; GMP, granulocyte-macrophage progenitor; HSC,

hematopoietic stem cell; LMPP, lymphoid-primed multipotent progenitor; MEP, megakaryocyte-

erythrocyte progenitor; MPP, multipotent progenitor; MSC, mesenchymal stromal cell; OB,

osteoblast; OC, osteoclast

13

2.2.1 Hematopoietic stem cells

The prevailing definition for murine hematopoietic stem cells is Lineage- Sca-1+ c-Kit+,

designated as LSK cells (Ikuta and Weissman 1992; Li and Johnson 1995) (Figure 4.). These

cells lack the lineage-associated surface markers but the expression of stem cell antigen 1

(Sca-1) and c-Kit (also termed receptor for stem cell factor or CD117) is high. HSCs can be

further classified into most primitive self-renewing stem cells, termed long-term

hematopoietic stem cells (LT-HSC), and into more differentiated short-term hematopoietic

stem cells (ST-HSC) and multipotent progenitors (MPP). LT-HSCs are able to reconstitute

the bone marrow of a transplanted animal. The ST-HSCs and MPPs, however, are capable

to only short-term reconstitution. The LT-HSCs reside in Thy1.1lo, CD34-, CD38+, Flt3- or

Hoechstlo fraction of the LSK population (Adolfsson et al. 2001; Goodell et al. 1996;

Morrison and Weissman 1994; Osawa et al. 1996; Randall et al. 1996). There seems to be no

clear-cut phenotypic definition, however, to distinguish ST-HSCs and MPPs from each

other (Iwasaki and Akashi 2007a). HSC compartment is heterogenous in respect of the

lineage and self-renewal potential of the cells and HSCs comprise distinct lineage biased

clonal subtypes (Beerman et al. 2010b). These HSCs with differential lineage potential can

be purified based on the expression of CD150 (Slamf1) (Beerman et al. 2010a). The human

HSCs are defined by the expression of surface markers CD34 and CD38, the most primitive

HSCs (LT-HSC) being lineage- CD34+ CD38- rhodaminelow (McKenzie et al. 2007).

2.2.2 Maintenance of self-renewal capacity of hematopoietic stem cells

Self-renewal capacity, i.e. a daughter cell maintaining its stem cell properties, is sustained

by both the intrinsic factors present in the stem cells and the extrinsic cues of the

microenvironment surrounding the cells. Many transcription factors, such as Gfi-1, Pbx1,

interferon regulatory factor-2, thioredoxin-interacting protein and Nurr-1 are known to be

important regulators of HSC quiescence (Li 2011). For example, Gfi-1 knockout in mice

leads to an increase in the numbers of cycling cells within the HSC pool and the function of

HSCs in bone marrow transplantation experiments is decreased (Hock et al. 2004). The

homeobox (Hox) transcription factors, such as Hoxb4 and Hoxa9, are widely studied

transcription factors indispensable for hematopoiesis. They are expressed preferentially in

HSC and immature progenitor cell populations and are down-regulated during the

differentiation of hematopoietic cells (Argiropoulos and Humphries 2007). The Hox family

transcription factors have overlapping functions and the loss of one gene may be

compensated for by the other members of this family. Quiescent HSCs have also a higher

expression of GATA-2, although its exact role in quiescence regulation in vivo is not clear

(Li 2011; Venezia et al. 2004). Additionally, p53 is important in ensuring that HSCs remain

quiescent and thus the increased expression of p53 is related to aging of hematopoietic cells

(Dumble et al. 2007). Several cytokines, such as IL-3, IL-6, IL-11, Flt-3 ligand,

thrombopoietin (TPO) and stem-cell factor (SCF, c-kit ligand), have been proposed as

regulators of HSC self-renewal and used in the in vitro expansion of HSCs (Blank et al.

2008). However, only studies with TPO and SCF have provided sufficient evidence to

support their important role as positive regulators of stem cell pool. The receptors for TPO

and SCF, c-mpl and c-kit respectively, are expressed on HSCs. Many signaling pathways

have been reported to regulate HSC self-renewal or promote expansion of these cells in

vitro, but nonetheless, their function in vivo has proved to be less pronounced. This

indicates that there are overlapping pathways to secure the control of HSC self-renewal.

14

The maintenance of the self-renewal capacity of HSCs and the promotion of

differentiation of committed cells are regulated also by epigenetic factors, such as DNA

methylation, histone modifications and non-coding RNA (Cedar and Bergman 2011; Scholz

and Marschalek 2012). DNA methyltransferases (DNMTs) catalyze the addition of a methyl

group to the 5’ position of the cytosine ring of DNA, especially to CpG dinucleotide

sequences. The N-terminal histone tails are subject to a vast array of covalent modifications,

including acetylation, methylation, ubiquitination, sumolation and phosphorylation. The

acetylation of histones H3 and H4 by histone acetyltransferases (HAT) promotes the

activation of transcription which is opposed by histone deacetylases (HDACs) that remove

acetyl groups, resulting in the formation of heterochromatin. Histone methylation by

histone methyltransferases (HMTs) can be a signal for either eu- or heterochromatin (active

or inactive chromatin). Methylation of H3K4 is known to signal for euchromatin whereas

methylation of H3K9 and/or H3K27 promotes the association of repressive proteins, such as

polycomb-group (PcG) proteins. The PcG proteins repress the genes that are involved in

cell-cycle regulation and differentiation (Radulovic et al. 2013). Bmi1 is one of the best

studied members of PcG family. It is specifically expressed in non-differentiated

hematopoietic cells and is required for HSC self-renewal. Although, there is no evidence

that Bmi1 overexpression could itself induce leukemia, it is believed to be an important

collaborating factor in leukemic transformation. Furthermore, other participants in

epigenetics have been shown to take part in leukemogenesis (Plass et al. 2008). Thus,

therapeutic agents targeting the enzymes of DNA methylation (DNMT inhibitors such as

decitabine (5-aza-2'-deoxycytidine)) and histone modifications (HDAC inhibitors such as

trichostatin A) are being actively developed, with some already in clinical use.

Since HSCs reside in an environment where the oxygen tension is very low, the

maintenance of low intrinsic oxidant levels has been proposed to be an important way of

keeping HSCs quiescent. The ROS level of HSCs is lower than the ROS level of committed

progenitor cells (Tothova et al. 2007). Forkhead transcription factors, FoxOs, have been

reported to protect HSCs from oxidative stress and triple knockout of FoxO1, FoxO3 and

FoxO4 resulted in an accelerated cycling of HSCs in mice (Tothova et al. 2007).

Additionally, mice deficient for ATM, a cell-cycle checkpoint regulator directly

downstream of FoxO3A, were shown to display increased ROS levels in HSCs which led to

a defect in maintenance of HSC quiescence (Ito et al. 2004).

2.2.3 Lineage commitment of hematopoietic cells

The expression of Sca-1 decreases in the more differentiated cell populations being, low in

common lymphoid progenitors (CLP) and negative in common myeloid progenitors (CMP,

Figure 4). The receptor for interleukin 7 (IL-7Rα) can be used to distinguish these two

populations from each other. IL-7Rα, an essential cytokine for T and B cell development, is

up-regulated in CLPs and absent in CMPs (Akashi et al. 2000; Bhatia et al. 1995; Kondo et

al. 1997). The mature blood cells of lymphoid lineage consist of small, round cells: T, B and

natural killer (NK) cells. Early lymphoid progenitors reside in bone marrow but the true

maturation of T cell lineage takes place in the thymus. Myeloid progenitors can be further

divided into three subsets on the basis of the expression of CD34 and FcγRII/III:

CD34+FcγRII/IIIlo CMPs, CD34-FcγRII/IIIlo megakaryocyte-erythrocyte progenitors (MEPs)

and CD34+FcγRII/IIIhi granulocyte-macrophage progenitors (GMPs). CMPs can produce all

types of myeloid colonies whereas MEPs and GMPs, which differentiate from the CMPs,

15

can generate only granulocytes (i.e. neutrophils, basophils and eosinophils), mast and

macrophage-dendritic cells or megakaryocytes and erythrocytes, respectively (Arinobu et

al. 2005; Iwasaki et al. 2005a). Dendritic cells can be derived also from CLPs (Manz et al.

2001). The monopotent megakaryocyte lineage-committed progenitors, giving rise to

platelets, have been identified in the CD9+ MEP fraction whereas the surface markers of

monopotent erythrocyte progenitors, giving rise to red blood cells, have not been

characterized (Iwasaki and Akashi 2007b; Nakorn et al. 2003).

Although the above definition for the distinct common lymphoid and myeloid

progenitors derived from MPPs is widely used, there is some evidence that the

differentiation routes of hematopoietic cells may be more complex [reviewed in (Iwasaki

and Akashi 2007a)]. The postulated model implies that myeloid differentiation can occur

not only through MPP-CMP pathway but also through lymphoid-primed multipotent

progenitors (LMPP) (Adolfsson, Mansson et al. 2005, Lai, Kondo 2006). LMPPs, defined by

the expression of Fms-like tyrosine kinase 3 (Flt3) and vascular cell adhesion protein 1

(VCAM-1), are lymphoid-biased but possess a granulocyte-macrophage potential. The

myeloid-potential is gradually down-regulated and eventually silenced during the course

of lymphocyte differentiation. The commitment to the lymphoid lineage is finally

established when the cell loses all of its abilities to produce cells with a myeloid lineage, i.e.

at the CLP stage. Megakaryocyte-erythrocyte differentiation is traditionally thought to

occur through the MPP-CMP pathway but there is also evidence that MEPs can be

generated directly from HSC-MPP compartment (Adolfsson et al. 2005; Friedman 2007;

Iwasaki et al. 2005b). LMPPs lack megakaryocyte-erythrocyte potential.

Figure 4 Differentiation path of murine hematopoietic stem and progenitor cells. The

hematopoietic stem cells and the myeloid and lymphoid progenitors can be identified and

divided into subtypes based on the expression levels of the surface markers c-Kit, Sca-1, CD34,

IL-7R and FcγRII/III. CLP, common lymphoid progenitor; CMP, common myeloid progenitor;

GMP, granulocyte-macrophage progenitor; LT-HSC, long-term hematopoietic stem cell; MEP,

megakaryocyte-erythrocyte progenitor; MPP, multipotent progenitor; ST-HSC, short-term

hematopoietic stem cell

16

2.2.4 Regulation of myeloid and megakaryocyte-erythroid lineage commitment

The lineage commitment is controlled by transcription factors that selectively activate or

silence a set of genes. The order in which certain transcription factors become expressed

and the expression level of transcription factor can decide the lineage outcome (Graf and

Enver 2009). The expression level and timing of transcription factors depend on both

intrinsic and extrinsic signals. Additionally, transcription factors may undergo cross-

antagonistic interaction with each other, inactivating transcription factors that direct the

differentiation of other cell types (Dahl et al. 2003; Nerlov et al. 2000; Rekhtman et al. 2003;

Zhang et al. 1999).

PU.1 is one of the most important regulators of hematopoietic lineage commitment. It is

highly expressed in myelomonocytic cells, B cells and at a lower level in their precursors,

such as HSCs, CMPs and CLPs (Akashi et al. 2000). PU.1 regulates myelolymphoid

differentiation and thereby its deficiency impairs the development of granulocytes,

macrophages and lymphocytes but does not have any impact on the development of

megakaryocytes or erythrocytes (McKercher et al. 1996; Scott et al. 1994). Conditional

knock-out models have demonstrated PU.1 to be necessary for the maintenance of HSCs

and indispensable in allowing MPPs to proceed to CMPs, GMPs and CLPs (Dakic et al.

2005; Iwasaki et al. 2005b). Moreover, PU.1 expression favors myeloid over lymphoid

development and monopoiesis over granulopoiesis (Dahl et al. 2003; DeKoter and Singh

2000). C/EBPs are expressed predominantly in granulocytes, monocytes and eosinophils

and C/EBPα also in HSCs, CMPs and GMPs but not in CLPs or MEPs (Friedman 2007;

Traver et al. 2001). Mice deficient in C/EBPα lack neutrophils and eosinophils whereas this

deficiency does not impact on lymphoid or megakaryocyte-erythrocyte development

(Zhang et al. 1997a; Zhang et al. 2004). Moreover, C/EBPα is required to allow CMPs to

proceed to GMPs as mice with a conditional deficiency of C/EBPα lack GMPs but the

development of CMPs, MEPs and CLPs is normal. However, C/EBPα is not absolutely

required for GMPs to differentiate into mature granulocyte-macrophages as demonstrated

by disruption of C/EBPα at GMP stage (Zhang et al. 2004). Disruption of PU.1 at GMP

stage, on the other hand, results in differentiation arrest (Iwasaki et al. 2005b).

GATA factors are essential transcription factors for the development of megakaryocytes

and erythrocytes (Iwasaki and Akashi 2007a). Enforced expression of GATA-1 in HSCs has

been shown to lead to an increase in megakaryocyte-erythrocyte differentiation (Zhang et

al. 2004). For further lineage specification, bipotent megakaryocyte-erythrocyte progenitors

require the presence of additional signals. Erythroid Krüppel-like factor (Kfl-1) and friend

leukemia integration 1 (Fli-1) have been identified as transcription factors directing

erythrocyte and megakaryocyte commitment, respectively (Mancini et al. 2012). GATA-2 is

crucial for the maintenance and proliferation of HSCs and multipotent progenitors (Vicente

et al. 2012). It is normally down-regulated as hematopoiesis proceeds and it is likely

repressed by GATA-1 (Crispino 2005).

2.2.5 Aging of the hematopoietic system

Similar to the homeostasis of other cellular systems, the cellular homeostasis of

hematopoietic system becomes disrupted with age. The most striking feature of an aging

hematopoietic system is the skewing towards a myeloid-biased output. The lymphoid

output, on the contrary, is decreased and adaptive immunity concomitantly diminished.

The incidence of myeloproliferative diseases increases with age whereas lymphoid

17

leukemias are more common in the young (Beerman et al. 2010b; Woolthuis et al. 2011).

Elderly humans and mice have also a greater propensity to anemia. The age-related

changes of hematopoietic system begins from HSCs whose population expands in

advancing age and the repopulation capacity diminishes (Beerman et al. 2010a; Rossi et al.

2005). During aging, the myeloid-biased (CD150high) HSC population expands whereas the

proportion of HSCs with balanced lineage output (CD150low) diminishes. A comparison of

old mice with their young counterparts has additionally revealed that the GMP population

expands with age whereas the frequencies of CMPs and MEPs do not differ from those of

young mice (Rossi et al. 2005). The gene expression profile of hematopoietic stem cells

changes with age and epigenetic factors have been postulated as being important in this

phenomenon (Woolthuis et al. 2011).

2.2.6 Bone marrow microenvironment

In recent years, it has become evident that the stromal cells surrounding solid tumors are in

close contact with the tumor cells and they can promote the transformation of these cells

into a malignant form. Hence, it is not surprising that also the microenvironment around

hematopoietic cells has been claimed to play a role in development of hematological

malignancies (Askmyr et al. 2011; Carlesso and Cardoso 2010). There is also evidence that

leukemic cells are able to influence bone cells and thereby may further contribute to the

severity of the hematopoietic disease (Edwards et al. 2008; Frisch et al. 2012).

Early in life, hematopoiesis occurs in the yolk sac, the aorta-gonadal-mesonephros region

and the liver. After bone forming cells (osteoblasts) have initiated the mineralization of the

bone extracellular matrix, the hematopoietic stem cells move to the bone environment and

in adults, hematopoiesis is localized in bone marrow. It is directed there by the calcium-

sensing receptor expressed on hematopoietic stem cells that enables cells to respond to

extra-cellular ionic calcium concentrations (Adams et al. 2006). The bone marrow

microenvironment is formed not only of the bone mineral matrix but also of cellular

components, such as mesenchymal stromal cells, bone forming and destroying cells,

perivascular cells and sympathetic neurons. Cells of the nervous system have been shown

to support HSC quiescence by influencing the molecular and cellular components of the

microenvironment (Katayama et al. 2006; Yamazaki et al. 2011). The vasculature of bone

marrow is also recognized as being an important factor for hematopoietic homeostasis

(Kopp et al. 2005). The most primitive HSCs are thought to line the endosteal walls of bones

whereas the more differentiated progenitors reside in close proximity to the vasculature

(Kopp et al. 2005; Zhang et al. 2003). HSCs from elderly individuals have been found to

localize more distantly from endosteum due to their reduced adhesion to stromal cells

(Kohler et al. 2009). Osteoblasts, lining the endosteal walls of bones, have been reported to

be one of the key cellular components maintaining hematopoiesis (Calvi et al. 2003). The

ablation of these cells leads to the concomitant loss of bone marrow cells (Visnjic et al.

2004). Osteoblasts maintain HSCs by secreting thrombopoietin (TPO) and by expressing

angiopoietin-1 (Ang-1), stem cell factor (SCF, c-kit ligand) and Jagged-1 on their surface

(Blank et al. 2008; Li 2011). Additionally, the adhesion molecules present in osteoblasts such

as N-cadherin, integrins and osteopontin anchor HSCs to the osteoblastic niche and

regulate the cell-cycle quiescence of HSCs. Adipocytes, on contrary, have been considered

to be negative regulators of hematopoiesis (Naveiras et al. 2009). In aging organisms,

adipocytes seem to displace the hematopoietic cells in the bone marrow.

18

2.3 BONE STRUCTURE, FUNCTION AND DEVELOPMENT

Bone serves a variety of functions providing, e.g. structural support and protection of

internal organs. In addition, it maintains the body’s mineral homeostasis and serves as

environment for hematopoiesis. Based on its structure, bone can be divided into cortical

and trabecular compartments (Bilezikian et al. 2008). Cortical bone is called also compact

bone due to its dense structure. It forms the hard outer layer of bones. Trabecular bone, on

the other hand, is a porous network inside the area that cortical bone has bordered. As a

result of its appearance, trabecular bone is often called spongy bone. In the long bones of

the limbs, trabeculae can be found at the ends of the bones (epiphyses).

Bone is a connective tissue consisting of cellular components, organic matrix and

inorganic elements (Bilezikian et al. 2008). Osteoblasts, osteoclasts and osteocytes are the

cellular components of bone, the latter accounting for 90 percent of bone cellularity. The

most abundant protein in the organic bone matrix, representing over 90% of all the bone

proteins, is type I collagen which is involved in the aligning of the mineral matrix. In order

to assemble collagen molecules into fibrils, procollagen needs to be cleaved by specific

proteinases. This process releases two propeptides, the amino-terminal PINP and carboxy-

terminal PICP whose serum concentrations reflect the rate of synthesis of type I collagen

and therefore have been used as markers of bone formation (Pollmann et al. 2007; Rissanen

et al. 2008). In addition, bone has also several non-collagenous proteins, such as osteopontin

(OPN), bone sialoprotein (BSP) and osteocalcin (OC). In fact, circulating levels of OC can be

used as a specific marker for osteoblastic activity and bone formation (Bilezikian et al.

2008). Bone proteins are bound to hydroxyapatite crystals, the inorganic calcium phosphate

constituent of the bone (accounting for approximately 60% of bone), and they serve

important functions in the regulation of mineralization.

During growth, bone formation occurs via two distinct mechanisms: intramembranous

and endochondral ossification (Clarke 2008). The flat bones are formed by

intramembranous ossification, a mechanism of direct bone formation. In endochondral

ossification, on the other hand, the pre-existing cartilage template is replaced by the

mineralized bone matrix. The cartilage growth plate has an integral role in the postnatal

linear growth of the long bones, nevertheless, the long bones are formed by combination of

these two mechanisms. The peak bone mass is achieved in adulthood, but thereafter bone is

lost as a result of the normal aging process. This means that the bone formation exceeds

bone loss in early life but the situation is reversed in the elderly.

2.3.1 Bone remodeling

After growth, bone appears to be a static organ. However, it is being constantly moulded

and renewed by a process termed remodeling (Eriksen 2010; Kular et al. 2012). Bone

remodeling allows repair of microdamage and replacement of old bone with new. It is

generally thought that the purpose of bone remodeling is to maintain the mechanical

properties of the skeleton as well as regulating mineral homeostasis. Remodeling is carried

out by the bone-resorbing osteoclasts, breaking down the old or damaged bone, and the

bone-forming osteoblasts, re-filling the gaps in the bone matrix. Signals from osteoclasts

and the products of the resorbed matrix partly regulate osteoblastogenesis and bone

formation (Martin and Sims 2005). However, human patients and mice with osteopetrosis

due to impaired osteoclast function have normal or increased numbers of functional

19

osteoblasts, thus indicating that it is the number of osteoclasts, rather than their activity

which is more crucial for osteoblastic bone formation (Karsenty 2000). Mesenchyme

derived cells, such as osteoblasts and osteocytes, are important regulators of

osteoclastogenesis and there are many regulatory factors influencing osteoclast formation.

Some of these influence the cells indirectly by stimulating expression of

osteoblastic/osteocytic receptor activator of nuclear factor kappa B ligand (RANKL).

Osteoblasts regulate osteoclastogenesis additionally by secreting macrophage colony

stimulating factor (M-CSF) (Udagawa et al. 1990). Previously, osteoblasts were thought to

be the major regulatory cell type involved in osteoclastogenesis but in recent years, the

important role of osteocytes has also been recognized (Xiong and O'Brien 2012).

Additionally, osteocytes secrete sclerostin, a protein which inhibits bone formation (van

Bezooijen et al. 2004).

In healthy young bone, the process of resorption and formation are tightly coupled to

maintain homeostasis and overall bone mass. Thus, a defect in either will cause an

imbalance in bone structure leading to a disease state. An imbalance in cellular processes of

bone remodeling is involved in serious bone diseases such as osteoporosis, osteosclerosis,

osteopetrosis and Paget’s disease of bone (Kular et al. 2012). Osteosclerosis and

osteopetrosis are diseases characterized by a marked increase in bone mass due to

stimulated osteoblast activity and osteoclast dysfunction, respectively. Osteoporosis, the

most common bone disease, on the other hand, is characterized by decreased bone mineral

density and by deranged levels and forms of bone proteins. Osteoporosis is classified into

primary and secondary diseases, with the primary form being further classified into

postmenopausal (in women) and age-related (both women and men) osteoporosis. The

pathophysiology of senile bone loss is characterized by bone formation exceeding bone

resorption on the periosteal surface and bone resorption exceeding bone formation on the

endosteal surface (Bilezikian et al. 2008; Clarke 2008). Consequently, bones increase in

diameter and the marrow space expands in the elderly. Osteoporosis is preceded by a state

called osteopenia in which there is a reduced bone mass, but not so extensive to fulfill the

criteria of osteoporosis.

2.3.2 Osteoblasts and bone formation

Osteoblasts are cells of mesenchymal origin (Dennis et al. 1999; Pittenger et al. 1999) (Figure

3). They are responsible for initial bone formation during development and later in bone

remodeling. The maturation of osteoblasts from mesenchymal progenitors consists of three

distinct phases: proliferation, extra-cellular matrix maturation and matrix mineralization.

After mineralization, the majority of osteoblasts undergo apoptosis whereas the remainder

of the population differentiates into osteocytes or quiescent bone lining cells. Osteocytes are

cells that become trapped inside the bone-matrix. They are able to sense a mechanical load

and subsequently send signals which cause bone to be either resorbed or formed.

The runt-related transcription factor 2 (Runx2) is viewed as the master regulator in

embryonic bone development as well as in postnatal differentiation and bone formation of

osteoblasts (see (Ducy et al. 1999; Komori 2003; Stein et al. 2004) for a review). Mice lacking

Runx2 do not produce any osteoblasts. Despite the essential role of Runx2 in osteoblast

commitment, it is not needed for the maintenance of the major bone matrix genes in mature

osteoblasts. Instead, it seems to function as a negative regulator of the terminal

differentiation of osteoblasts (Liu et al. 2001; Marie 2008; Maruyama et al. 2007). Among

20

many other signaling pathways, Wnt/β-catenin pathway has been shown to be an

important promoter of osteoblastogenesis through the stimulation of Runx2 (Gaur et al.

2005). The bone cell phenotype is further reinforced by transcription factor Osterix (OSX)

(Nakashima et al. 2002). OSX is believed to act downstream of Runx2 during osteoblast

differentiation since it is not expressed in Runx2-deficient embryos but Runx2 is expressed

in Osx-deficient mice. After proliferation, the expression of bone-matrix genes, such as type

I collagen and fibronectin, increase in pre-osteoblasts and these cells turn into bone-matrix-

secreting osteoblasts. The expression of bone-matrix proteins osteocalcin, octeopontin and

bone sialoprotein is increased in the mineralization phase in response to Runx2 promotion

(Ganss et al. 1999; Neve et al. 2013; Sodek et al. 2000). These bone-matrix proteins have high

affinity for the mineral constituent of bone, the hydroxyapatite crystal. The mineralization

of the secreted matrix requires the presence of tissue non-specific alkaline phosphatase

(TNAP/ALP), whose expression is increased along with the genes encoding bone-matrix

proteins (Orimo 2010). ALP hydrolyzes pyrophosphate and provides the inorganic

phosphate needed for hydroxyapatite crystallization. The hydroxyapatite crystals are

formed within the matrix vesicles of osteoblasts (and chondrocytes) and deposited between

collagen fibrils. Deactivating mutations in the TNAP gene are responsible for poorly

mineralized cartilage and bones and also the accumulation of pyrophosphate.

2.3.3 Osteoclasts and bone resorption

Osteoclasts are multinucleated gigantic cells derived from the monocyte-macrophage

lineage of hematopoietic cells (Walker 1975) (Figure 3). Despite sharing some cell-surface

markers with macrophages, osteoclasts differ clearly from these cells, most distinctively by

their ability to excavate bone (Chambers 2000). Upon reaching the bone matrix,

mononuclear precursors fuse to form multinucleated osteoclasts which then become

polarized. These polarized osteoclasts generate an isolated environment (sealing zone)

between themselves and the bone and begin the degradation with the resorbing membrane

(ruffled border) (Vaananen and Horton 1995). Osteoclasts secrete protons to lower the pH

and, thus, are able to dissolve minerals from the bone-matrix (Bilezikian et al. 2008).

Additionally, the matrix osteoclasts secrete enzymes, such as matrix metalloproteinases

(MPPs) and cysteine proteinases, especially cathepsin K (CTSK), which degrade the organic

components. When CTSK degrades the bone-matrix, collagen fragments, such as carboxy-

terminal cross-linking telopeptide (CTX), are released and thus the serum concentration of

CTX reflects the resorbing activity of osteoclasts. The bone degradation products are

transcytosed into vesicles via the resorbing osteoclasts from the ruffled border to the basal

membrane. Tartrate-resistant acid phosphatase (TRAcP) is believed to function in the

vesicles to undertake the final steps in the destruction of matrix components. The serum

concentration of TRAcP5b has been shown to reflect the number of osteoclasts (Alatalo et

al. 2004). After resorption, osteoclasts are subjected to apoptosis. The master transcriptional

regulator of osteoclastogenesis is nuclear factor of activated T cells cytoplasmic 1 (NFATc1)

(Zhao et al. 2010). NFATc1 regulates the expression of genes encoding adhesion molecules,

proton pumps and bone-matrix degradation proteins, thus, modulating osteoclast

migration, adhesion, differentiation and activation. NFATc1 is activated by RANKL

signaling which leads to the activation of several downstream molecules, for example NF-

κB, c-jun and c-fos.

21

3 Aims of the study

The main purpose of this study was to investigate the effects of activated polyamine

catabolism on hematopoiesis and bone remodeling, and to evaluate the interplay between

these two processes.

The specific aims were:

To investigate the response of SSAT overexpressing mice to an immunological

challenge

To characterize the hematopoietic phenotype of SSAT overexpressing mice and to

assess the factors affecting the phenotype

To assess the role of SSAT activity in human lymphoid and myeloid leukemias

To characterize the bone phenotype of SSAT overexpressing mice and to elucidate

the molecular mechanisms underlying the changes

22

23

4 Materials and methods

4.1 PATIENT SAMPLES

Peripheral blood mononuclear cells (PBMCs) were obtained from 21 CML, 28 AML and 33

ALL patients at time of diagnosis. Blood samples from AML and ALL patients were

collected in the Department of Medicine at Kuopio University hospital in the years

2001─2004. PBMCs were isolated (CPTTM tubes, BD Biosciences, Franklin Lakes, NJ) and

stored at the Laboratory of Eastern Finland. Blood samples from CML patients were

collected at the Helsinki University Central Hospital (Helsinki, Finland) during years

2004─2011. PBMCs from CML patients were separated with Ficoll centrifugation (GE

Healthcare Bio-Sciences, San Jose, CA, USA). Control PBMCs were obtained from healthy

donors (n=5─12). The use of mononuclear cells taken at diagnosis in AML and ALL patients

was accepted by the Ethical Committee of the North Savo Hospital District and by the

National Supervisory Authority for Welfare and Health. The collection of samples from

CML patients was approved by the Helsinki University Central Hospital Ethics. Written

informed consents were obtained from all patients prior to sample collection.

4.2 MICE

Mice overexpressing the SSAT gene under its endogenous promoter (SSAT mice), their

wild-type littermates (wt) and mice deficient in SSAT (SSATKO mice) were used in the

experiments (Niiranen et al. 2006; Pietila et al. 1997). SSAT and wild-type mice were in

C57BL/6JOlaHsd and SSATKO in C57BL/6J background. All animal experiments were

approved by the National Animal Experiment Board of Finland.

In the LPS experiments, mice were given a single intraperitoneal injection of

lipopolysaccharide (LPS, E. coli strain 0111:B4, Sigma-Aldrich, 2 mg/kg as the non-lethal

dose, 15 mg/kg or 30 mg/kg as the lethal dose) or saline (controls), n=3─10/group. Mice were

monitored once every 1 to 2 hours and sacrificed at different time-points (and if in a

moribund state). In bone marrow transplantation, the recipient mice (n=8─10/group) were

lethally irradiated twice with a dose of 5.5 Gy (fractions 3 hours apart) one day before the

transplantation. Donor bone marrow cells (5x106 cells/ 200 µl of PBS-2% FBS) were injected

into the tail vein of the recipient mice under anesthesia. In cell proliferation studies, 1 mg of

BrdU (BrdU Flow Kit, 557891, BD Biosciences, San Jose, CA) in PBS was administered

intraperitoneally ten to eleven hours before sacrifice (n=6/group). In studies treating mice

with drugs affecting epigenetic factors, the animals were subjected to daily intraperitoneal

injections of decitabine (0.2 mg/kg, 5-Aza-2’-deoxycytidine, Sigma-Aldrich, St. Louis, MO,

n=5─11) or trichostatin A (1 mg/kg, Selleck Chemicals, Houston, TX, n=7─9) for seven and

ten days, respectively. Control animals received intraperitoneal PBS at a dose of 10 ml/kg.

4.3 ISOLATION OF BONE MARROW CELLS FROM MICE

Bone marrow cells were isolated from the bone marrow cavities of the hind legs by flushing

with PBS-10% FBS. The cells were filtered through 40 µm strainers before being used in

24

flow cytometry (n=6─8 mice/group) or bone cell (osteoblasts and osteoclasts) differentiation

experiments.

4.4 EXPANSION OF FACS-SORTED LSK CELLS

Sorted LSK cells pooled from six to eight mice were grown for 16 hours at 37ºC in 5% CO2

in IMDM (Iscove’s modified Dulbeccos medium) supplemented with 1% BSA, 0.1 mM 2-

mercaptoethanol, 2 mM glutamine, human transferrin (200 µg/ml), bovine pancreatic

insulin (10 µg/ml), low density lipoproteins (40 µg/ml), human Flt-3 ligand (100 ng/ml),

human IL-11(100 ng/ml) and murine SCF (50 ng/ml).

4.5 DIFFERENTIATION OF MESENCHYMAL STROMAL CELLS TO OSTEOBLASTS

Osteoblast differentiation from mesenchymal stromal cells was conducted as described

previously (Heino and Hentunen 2008). Shortly, bone marrow cells isolated from 4‒5 weeks old

mice (n=4─6) were cultured in αMEM supplemented with 15% FBS, 10 mM HEPES, 50

µg/ml gentamycin and 10 nM dexamethasone for one week at 37°C with 5 % CO2. Free-

floating cells were removed at day two of culture. Adherent cells, enriched for

mesenchymal stromal cells, were detached by trypsin treatment and plated in six-well

plates with 150 000 cells /well or in 24-well plates with 30 000 cells /well. Differentiation of

osteoblasts was initiated by adding 10 mM Na-β-glycerophosphate (Sigma-Aldrich, St.

Louis, MO) and 70 µg/ml ascorbate-2-phosphate (Sigma-Aldrich, St. Louis, MO).

Dexamethasone was omitted on the third day of differentiation. The medium was changed

on every third day and the cells were differentiated for up to 21 days.

4.6 DIFFERENTIATION OF HEMATOPOIETIC CELLS TO OSTEOCLASTS

Non-adherent bone marrow cells isolated from 4‒5 weeks old mice (n=4─6) were cultured

in αMEM supplemented with 10% FBS, 50 µg/ml gentamycin and 5 ng/ml M-CSF (Merck

Millipore, Billerica, MA) at 37°C with 5 % CO2. After 24 hours, the medium was changed to

contain 30 ng/ml M-CSF. After an additional 48 hours, the cells were plated in equal

numbers and osteoclast formation was induced by addition of 35 ng/ml RANKL (Merck

Millipore, Billerica, MA).

4.7 STATISTICAL ANALYSES

Data are presented as mean ± SD when applicable. GraphPad Prism 5.03 software package

(GraphPad Software Inc., LaJolla, CA) was used to perform the unpaired two-tailed

Student’s t test and Pearson’s correlation analyses. P value < 0.05 was considered to be

statistically significant.

4.8 ANALYTICAL METHODS

Peripheral blood samples were collected from hind leg saphenous vein or directly from the

hearts of sacrificed mice into EDTA (ethylenediaminetetraacetic acid) -coated or serum

25

separator tubes (BD Diagnostic, Franklin Lakes, NJ). Table 1 lists the methods used to

measure blood and serum analytes in the original publications I─IV. Table 2 summarizes

the methods used to analyze tissue and cell samples as described in detail in the original

publications (indicated in the table).

Table 1. Analyses of blood and serum samples in original publications I─IV

Analyte/ analysis

Reference/kit/instrument Method Publ

Blood count Sysmex k-4500 haematology analyser Flow cytometry II, III

PINP Rat/mouse PINP EIA (IDS) EIA IV

TRAcP5b Mouse TRAP Assay ELISA kit (IDS) ELISA IV

OC Mouse osteocalcin RIA kit (Biomedical

technologies Inc)

RIA IV

CTX RatLaps (CTX-I) EIA kit (IDS) EIA IV

ALAT ALAT (GPT) FS* (IFFC mod.) kit (DiaSys) Spectrophotometry I

Creatinine Merckotest Creatinine kit (Merck) Spectrophotometry I

IL-1β Bioplex Pro mouse cytokine kit (Bio-Rad) BioPlex 200 System I

IL-6 Bioplex Pro mouse cytokine kit (Bio-Rad) BioPlex 200 System I

IL-10 Bioplex Pro mouse cytokine kit (Bio-Rad) BioPlex 200 System I

INF-γ Bioplex Pro mouse cytokine kit (Bio-Rad) BioPlex 200 System I

TNF-α Bioplex Pro mouse cytokine kit (Bio-Rad) BioPlex 200 System I

IgA (Kankaanpaa et al. 2009; Nissinen et al. 2012) Chemiluminescent

immunoassay

II

IgM (Kankaanpaa et al. 2009; Nissinen et al. 2012) Chemiluminescent immunoassay

II

IgG (Kankaanpaa et al. 2009; Nissinen et al. 2012) Chemiluminescent immunoassay

II

26

Table 2. Methods used to analyze samples in the original publications

Method/analysis Tissue/cells Reference/kit Publ

Cell smear PB, BM REASTAIN Quick-Diff kit (Reagena)

II

Histology L, K, S, Th, LN, BM I─II

von Kossa staining OB (Leskela et al. 2003) IV

Bone length and diameter F, T IV

Ash weight T IV

Micro-computed tomography

T (Bouxsein et al. 2010; Maatta et al. 2013)

IV

Biomechanical analysis F, T (Jamsa et al. 2001) IV

ALP activity OB (Leskela et al. 2003) IV

Polyamine concentration

(HPLC)

L, K, S, LN, BM, PBMC, OB, OC (Hyvonen et al. 1992) I─IV

SSAT activity L, K, S, LN, BM, PBMC, OB, OC (Bernacki et al. 1995) I─IV

ODC activity L, K, S, LN, BM, PBMC, OB, OC (Janne and Williams-Ashman 1971)

I─IV

RNA analysis L TRIzol reagent (Invitrogen), High Capacity cDNA Reverse

Transcription Kit (AB)

I

Quantitative real-time PCR LSK RNeasy Mini Kit (Qiagen), High Capacity cDNA Reverse

Transcription Kit (AB)

II

Quantitative real-time PCR OB, OC TRIzol reagent (Invitrogen), High Capacity cDNA Reverse Transcription Kit (AB)

IV

Western blot PBMC III

Protein concentration L, K, S, LN, BM, LSK, PBMC, OB, OC

Protein assay kit (Bio-Rad) I─IV

Magnetic separation BM Mouse hematopoietic progenitor cell enrichment kit (Stemcell Technologies)

II

Flow cytometry PB, S, BM, LSK II

PB, peripheral blood; BM, bone marrow; L, liver; K, kidney; S, spleen; Th, thymus; LN, lymph node; F, femur; T, tibia; OB, osteoblast; OC, osteoclast; PBMC, peripheral blood mononuclear cell; LSK, Lineage-

Sca-1+cKit+ hematopoietic stem cell

27

5 Results

5.1 EFFECTS OF ACTIVATED POLYAMINE CATABOLISM IN IMMUNE

RESPONSE (I)

To monitor whether the immune response of SSAT mice was altered compared to wild-type

mice, the immune system of these mice was challenged with lipopolysaccharide (LPS). LPS

is a structural constituent of the outer membrane of gram-negative bacteria. It activates

immune and liver cells to produce pro- and anti-inflammatory mediators and ultimately

causes endotoxemia leading to septic shock (Pinsky 2004). SSAT mice and wild-type mice

had similar survival rates after administration of a lethal dose of LPS (I, Fig 1). However,

SSAT mice begun to show early signs of inflammation (e.g. diarrhea and lethargy) slightly

before their wild-type littermates. The histopathological changes observed in liver and

kidneys after a non-lethal LPS challenge were similar in SSAT and wild-type mice (I, Fig 3

and 4). The creatinine levels were also similar in both genotypes whereas serum ALAT

activities were significantly higher in SSAT mice in comparison with the wild-type

littermates (I, Fig 2). Thus, the liver of SSAT mice was affected to a greater extent than the

liver of the wild-type mice to the LPS challenge. Serum concentrations of pro-inflammatory

cytokines TNF-α and IL-6 were similar in SSAT and wild-type mice after a non-lethal LPS

challenge whereas the increase in IL-1β and INFγ concentrations was greater in the wild-

type than in the SSAT mice (I, Fig 5). On the other hand, the concentration of the anti-

inflammatory cytokine IL-10 was higher in SSAT mice than in wild-type mice. The

expression levels of hepatic acute-phase proteins C-reactive protein (CRP), haptoglobin and

alpha-1-acid glycoprotein (AGP1) were increased in SSAT mice after a non-lethal LPS

challenge whereas the level of expression of serum amyloid A (SAA1) was comparable to

that of wild-type mice (I, Fig 6). In the basal state, levels of serum cytokines and hepatic

acute-phase proteins showed no differences between genotypes. The lethal LPS challenge

increased ODC activity in kidneys and liver in both genotypes (I, Tables 1 and 3). SSAT

activity, on the other hand, was enhanced only in SSAT mice. Polyamine levels changed in

accordance with the enzyme activities, i.e. putrescine was increased in both tissues in both

genotypes, spermidine was decreased in liver and spermine in kidneys of SSAT mice. A

non-lethal LPS challenge increased hepatic ODC activity and renal SSAT activity in SSAT

mice (I, Table 2 and 4). The wild-type mice displayed no major changes in enzyme levels in

either tissue. (Renal ODC activity was not analysed.) However, putrescine accumulated in

both tissues in both genotypes. In addition, wild-type mice showed an increased level of

spermidine in both tissues after the LPS challenge. N1-acetylspermidine accumulated

mainly only in SSAT mice.

28

5.2 EFFECTS OF ACTIVATED POLYAMINE CATABOLISM ON HEMATOPOISIS IN MICE (II)

5.2.1 Polyamine cycle is enhanced in hematopoietic cells of SSAT mice

Polyamine metabolism was disturbed in SSAT overexpressing mice in all of the

hematopoietic tissues investigated, i.e. bone marrow, spleen, peripheral blood mononuclear

cells, lymph nodes and macrophages (II, Fig 4, bone marrow). SSAT activity was

significantly elevated as also was the activity of the biosynthetic enzyme ODC. Putrescine

became highly accumulated and, uncharacteristically for mammalian cells, its concentration

exceeded that of spermidine and spermine. In fact, the spermidine and spermine

concentrations were decreased. Furthermore, the activity of SSAT increased N1-

acetylspermidine levels. The level of bone marrow SSAT activity was observed to be

associated with the number of cells in bone marrow and with the weight of spleen.

5.2.2 SSAT mice exhibit myeloproliferative phenotype

The blood count of SSAT mice started to exhibit changes at sexual maturation and the

changes became more drastic at an older age (II, Table 1). The number of mature

neutrophils increased with age at the expense of lymphocytes which resulted in an elevated

proportion of neutrophils. The number of platelets was significantly elevated after two

months of age and in old SSAT mice there was evidence of anemia, due to a decreased

number of erythrocytes. The splenic proportion of T cells (CD3+) was decreased and the

proportion of B cells (B220+) was increased in SSAT mice (II, Table 2). Additionally, serum

IgG levels were increased in SSAT mice compared to the wild-type. The ratio of CD4-

positive helper T cells to CD8-positive cytotoxic T cells (CD4+/CD8+) was significantly

reduced and the proportion of regulatory T cells (CD4+CD25+FoxP3+) from all T cells was

significantly higher in the peripheral blood and spleen of SSAT mice. Additionally, spleens

were enlarged in SSAT mice (II, Fig 3). However, the histological sections of spleen, thymus

and liver revealed no morphological differences between SSAT and wild-type mice and no

infiltration of leukocytes or extramedullary hematopoiesis was observed in the liver of

these mice. Bone marrow cellularity was significantly higher in SSAT mice and their bone

marrow exhibited enhanced myelopoiesis and thrombocytopoiesis (II, Fig 2 and 3). The

bone marrow architecture, however, was normal and no fibrosis was detected. The

proportion of blast cells in the bone marrow remained unchanged. The numbers and

proportion of common myeloid progenitors (CMP) and megakaryocyte-erythrocyte

progenitors (MEP) from all bone marrow cells were significantly decreased whereas the

numbers and proportion of granulocyte-macrophage progenitors (GMP) were elevated in

SSAT mice (II, Fig 6). The number and proportion of LSK cells (including hematopoietic

stem cells and multipotent progenitors) and more specifically, long-term hematopoietic

stem cells (LT-HSC) also increased in SSAT mice. Proliferation of LSK cells was found to be

increased in SSAT mice. However, there were no changes in the phases of cell cycle or in

apoptosis of sorted LSK cells expanded in cell culture for 4 days. The expression of HSC

self-renewal regulators Gfi1, Bmi1, GATA-2 and HoxB4 was comparable between wild-type

and SSAT LSK cells as was the expression of a myeloid lineage commitment regulator

C/EBPα. The expression of the megakaryocyte-erythrocyte commitment factor GATA-1 was

increased whereas that of the myelo-lymphoid commitment regulator PU.1 declined in LSK

cells.

29

5.2.3 The myeloproliferative phenotype of SSAT mice results from both the intrinsic

factors of bone marrow cells and the bone marrow microenvironment

Blood count analysis revealed that after short-term transplantation (up to ten weeks) wild-

type and SSAT recipients injected with SSAT bone marrow as well as the SSAT recipients

receiving wild-type cells displayed an increased proportion of neutrophils compared with

the wild-type animals transplanted with wild-type bone marrow (II, Fig 5). Neutrophilia

remained present in all SSAT recipients after long-term reconstitution whereas the wild-

type environment attenuated blood count in long-term reconstitution in wild-type mice

that received SSAT bone marrow. The most prominent phenotype was observed in those

SSAT mice transplanted with SSAT bone marrow. The number of bone marrow cells was

increased only in the SSAT recipients at the time of sacrifice (26 weeks). However, the size

of the spleen was significantly increased in all SSAT recipients as well as in wild-type

recipients transplanted with SSAT bone marrow in comparison to wild-type mice

transplanted with wild-type bone marrow. The bone marrow cells of SSAT recipients and

the wild-type mice transplanted with SSAT bone marrow had increased SSAT activity, an

increased amount of putrescine as well as reduced levels of spermidine compared to wild-

type mice transplanted with wild-type bone marrow.

5.3 SSAT ACTIVITY IN MYELOID AND LYMPHOID LEUKEMIAS AND EPIGENETICS IN HEMATOPOIETIC CELLS OF SSAT OVEREXPRESSING MICE (III)

5.3.1 Polyamine metabolism of human leukemic blood cells is disturbed

Levels of spermidine and spermine were significantly increased in peripheral blood

mononuclear cells (PBMCs) of acute myeloid leukemia (AML), chronic myeloid leukemia

(CML) and acute lymphoid leukemia (ALL) (III, Fig 1) patients compared with the healthy

controls and the levels correlated positively with peripheral blood white blood cell (WBC)

count and blast percentage. Additionally, the activity of SSAT was increased in all leukemia

types. Interestingly, in myeloid leukemia patients (AML and CML), but not ALL patients,

with the peripheral WBC count above the reference range SSAT activity was increased

compared with the patients with normal or low peripheral blood WBC count. The SSAT

activity correlated positively with the peripheral blood WBC count. After treatment, both

the PBMC SSAT activity and WBC count of the follow-up samples of CML patients

declined to the level of healthy controls. The activity of ODC and the level of putrescine

were elevated only in ALL patients and the ODC activity correlated negatively with WBC

count and blasts percentage.

5.3.2 SSAT mice show epigenetic changes in hematopoietic cells and differential

response to drugs affecting epigenetic factors

The amount of methylation was significantly increased in tri-methylated lysine 36, 9 and 4

residues and also in di-methylated lysine 79 residue of histone 3 in the bone marrow cells of

SSAT mice compared to wild-type mice (III, Fig 4). The acetylation of histone 3 in lysine 9

and lysine 14 residues and the level of histone deacetylase 1 (HDAC1) were also slightly

increased in the bone marrow cells of SSAT mice compared to wild-type mice. Seven day

treatment with decitabine, a DNA methyltransferase inhibitor used as an antileukemic drug

in the therapy of human myeloid malignancies, evened up the changes in the peripheral

30

blood granulocytic and lymphoid cells between SSAT and wild-type littermates (III, Fig 2).

In addition, the bone marrow cell number of SSAT mice was equal to that of the wild-type

mice after treatment with decitabine. The SSAT activity of the bone marrow cells was not

affected by the treatment. Ten day treatment with trichostatin A, a histone deacetylase

inhibitor, did not affect WBCs of SSAT mice but significantly decreased the proportion and

number of lymphocytes and increased the proportion of neutrophils in wild-type mice (III,

Fig 3). The treatment also reduced the total WBC count in wild-type animals whereas in

SSAT mice, the WBC count was unaltered.

5.4 EFFECTS OF ACTIVATED POLYAMINE CATABOLISM ON BONE REMODELING (IV)

5.4.1 Polyamine metabolism of osteoblasts and osteoclasts is disturbed

Polyamine metabolism of in vitro differentiated osteoblasts of SSAT overexpressing mice

showed significantly increased SSAT activity, accumulation of putrescine and a decreased

level of spermidine (IV, Fig 5). The spermine level was unaltered and there was no

accumulation of the acetylated forms of polyamines. Interestingly, ODC activity was

reduced in SSAT osteoblasts differentiated for 14 days but it increased as differentiation

proceeded further. In SSATKO osteoblasts, ODC activity was decreased, the putrescine

level was significantly reduced whereas spermidine and spermine levels remained

unaltered when compared to wild-type osteoblasts. Polyamine metabolism of in vitro

differentiated SSAT osteoclasts showed increased SSAT and ODC activities and

accumulation of putrescine (unpublished data). Spermidine and spermine levels were

unchanged and no acetylated forms of polyamines were detected.

5.4.2 SSAT overexpression affects osteoblastogenesis but not osteoclastogenesis cell-

autonomously

Mesenchymal stromal cells of SSAT mice differentiated into osteoblasts in cell culture

showed decreased ALP enzyme activity and a decreased number of mineralized calcium

nodules as compared to osteoblasts of wild-type littermates indicating impairment in

osteoblastogesis (IV, Fig 4). In contrast to SSAT osteoblasts, SSATKO osteoblasts showed

increased osteoblastogenesis. The expression of the osteoblastogenic regulator OSX as well

as of the osteoblastogenic marker genes ALP, OC, OPN and BSP were decreased in SSAT

osteoblasts. On the other hand, expression of RUNX2, the master regulator of

osteoblastogenesis, was not changed. However, as differentiation proceeded, the expression

of RUNX2 and ALP increased, whereas that of the other genes was still significantly lower

in SSAT osteoblasts as compared to the level of expression in wild-type cells. In vivo, the

serum concentration of PINP, a marker of collagen deposition and thus bone formation,

was slightly elevated in SSAT mice compared to wild-type mice (IV, Fig 3). The serum

concentration of OC, a protein binding bone mineral matrix, on the other hand, was

reduced in SSAT mice. The numbers of osteoclasts, differentiated in vitro from bone

marrow cells, were comparable in wild-type and SSAT mice. The expression of the

osteoclastogenic regulator NFATC1 was significantly increased in the osteoclasts of SSAT

mice (IV, Fig 4). However, that did not reflect to the expression levels of the

osteoclastogenic markers, TRACP and CTSK, as their levels were unaltered. In vivo, the

concentration of the bone resorption marker reflecting the number of osteoclasts, TRACP5b,

31

was decreased in SSAT mice whereas the concentration of a marker of osteoclast activity,

CTX, was comparable with that found in wild-type mice (IV, Fig 3).

5.4.3 Induction of SSAT with α-methylspermidine disturbs wild-type

osteoblastogenesis

Treatment of SSAT osteoblasts with α-methylspermidine did not have any effect on their

defective differentiation potential (IV, Fig 6). The ALP activity of SSATKO osteoblasts was

slightly, but statistically significantly, decreased after treatment with the analogue.

Nevertheless, it remained markedly increased as compared to ALP activity of wild-type

and SSAT osteoblasts. ALP activity and the number of mineralized nodules of wild-type

osteoblasts, however, decreased to the level of those in SSAT osteoblasts after treatment

with the analogue. α-Methylspermidine induced SSAT activity in wild-type and SSAT cells

but not in SSATKO cells lacking a functional SSAT gene. The activity of ODC was

decreased similarly in all three genotypes compared to their untreated counterparts. The

levels of natural polyamines decreased drastically in all three genotypes and they were

replaced by the analogue.

5.4.4 Bone phenotype of SSAT mice reveals striking changes

The skeleton of SSAT mice started to show changes at sexual maturation revealing

kyphosis (hunched back). The diameter of femurs and tibiae were larger in SSAT mice (IV,

Table 1). The length of the bones was increased only in males at the age of 5 months. The

diameter and length of long bones of SSATKO mice, however, were unaltered. The bone

mineral content of tibiae was increased in young SSAT mice but comparable between the

three genotypes at older age. The bones of SSAT mice broke more easily than the bones of

wild-type mice when subjected to compression whereas biomechanical studies showed that

in response to a bending force, the bones of female SSAT mice had greater stiffness and

strength (IV, Fig 2). The bones of male SSAT mice showed increased tibial but not femoral

stiffness and strength. In contrast to SSAT mice, the bone strength of SSATKO mice in

response to bending was slightly decreased in the tibiae in females and in the femur necks

of the males. An investigation of tibiae of SSAT and SSATKO mice by computational micro-

tomography revealed drastic differences in their structure compared to wild-type mice (IV,

Fig 1). The endosteal tissue volume (TV) of cortical bone was significantly larger in SSAT

mice and the BV/TV ratio was significantly decreased. Additionally, the bone perimeter

(B.Pm) showed a significant increase in SSAT mice whereas the cross-sectional thickness

(Cs.Th) was reduced. The trabecular thickness (Tb.Th) was reduced and total volume of

porosity (Po.V) was larger in SSAT mice. Additionally, in the 7 month old SSAT mice, the

trabecular number (Tb. N) was increased. In SSATKO mice, both the cortical BV and TV

were reduced resulting in a BV/TV ratio which was comparable to that in the wild-type

mice. B.Pm and Cs.Th were unaltered in SSATKO mice. The Tb. N was reduced in SSATKO

mice compared to wild-type. The bone mass density (BMD) was similar in SSAT and wild-

type mice whereas it was decreased in SSATKO mice when compared to wild-type mice.

32

33

6 Discussion

SSAT is the key catabolic enzyme of polyamines. Activation of SSAT in mice concurrently

enhances the whole polyamine cycle in many tissues which in addition to affecting

polyamine levels, influences the availability of metabolites shared with other metabolic

pathways and increases the production of toxic metabolites. The present work has

characterized the role of enhanced polyamine catabolism in immune defense,

hematopoiesis and bone remodeling.

I Inflammatory challenge of SSAT mice

Neutrophils are the first cells recruited to acute inflammatory sites. They bind surface

structures of pathogens, such as lipopolysaccharide (LPS) of gram-negative bacteria. In

consequence, neutrophils begin to produce cytokines to recruit other immune cells as well

as enzymes and reactive oxygen species (ROS) to kill ingested bacteria. During the early

stages of endotoxic shock neutrophils are known to be essential for suppression of

bacteremia and the preservation of tissue function (Hoesel et al. 2005). However, in the later

stages of endotoxic shock, neutrophils are themselves significant contributors to tissue

damage and organ failure. These present results show that after exposing animals to a

lipopolysaccharide (LPS) -induced endotoxic shock, the anti-inflammatory actions were

enhanced and pro-inflammatory actions inhibited earlier in SSAT mice than in wild-type

mice. Although, SSAT mice revealed an enhanced anti-inflammatory response at the

molecular level during the early stage of LPS challenge, this had no effect on the mortality

of these mice as it was comparable to their wild-type counterparts. The increased

neutrophil numbers of SSAT mice (II) and the harmful effects of neutrophils at later stages

of endotoxic shock could explain the end result of the inflammatory challenge. In further

support of this proposal, SSAT mice had increased alanine aminotransferase (ALAT) values

at 24 hours after the LPS-challenge, evidence of greater liver damage in the late stage of

endotoxic shock.

II-IV SSAT in myeloproliferation and association of hematopoiesis and bone phenotype

in SSAT mice

These present studies demonstrated that overexpression of SSAT in mice evoked a

myeloproliferative phenotype that emerged at sexual maturity and progressed with age.

The hematological phenotype of SSAT mice fulfilled the criteria of a myeloproliferative

disease, according to the Bethesda proposal for classification of murine nonlymphoid

hematopoietic neoplasms (Kogan et al. 2002). This was supported by the immunological

studies which revealed that the basal levels of serum cytokines and acute phase protein

expressions were comparable between SSAT and wild-type mice (I), thus suggesting that

SSAT mice do not suffer from a systemic chronic inflammation. Furthermore, the

hematological phenotype of SSAT mice was shown to originate partly from the intrinsic

SSAT overexpression of hematopoietic cells as demonstrated by transplantation

experiments. However, the bone marrow microenvironment was also shown to contribute

to the development of myeloproliferation in SSAT mice with the most prominent

hematopoietic phenotype being encountered when both the SSAT bone marrow cells and

34

the SSAT microenvironment were present. Nevertheless, the changes seen in bone structure

and in bone forming cells of SSAT mice were in line with the increased hematopoiesis (IV).

The myeloproliferative phenotype of SSAT mice implied that there had been changes in

lineage commitment. This was indeed apparent already at the hematopoietic stem cell

(HSC) level as the expression level of the lineage marker PU.1 was decreased and that of

GATA-1 increased when compared to the expression levels in wild-type HSCs. PU.1 is an

important regulator of the myelolymphoid lineage commitment and GATA-1 an essential

transcription factor for the lineage commitment of megakaryocytes and erythrocytes at the

HSC level (Iwasaki et al. 2005b; Iwasaki and Akashi 2007b). Mature granulocytic cells were

extensively accumulated in the hematopoietic tissues of SSAT mice at the expense of

lymphoid cells. This myeloid domination was apparent already at the progenitor level as

the numbers of granulocyte-macrophage progenitors (GMPs) were elevated in SSAT mice.

In addition to granulocytic accumulation, SSAT overexpression led to an increase in the

number of platelets in SSAT mice as compared to wild-type mice whereas the numbers of

MEPs, the common progenitor for megakaryocytes and red blood cells, were reduced as

were those of mature erythrocytes. The findings from the mouse model were

complemented by the studies of polyamine metabolism in human leukemia samples which

revealed that the SSAT activity was associated with the white blood cell count in patients

with myeloid leukemias (III). In contrast in lymphoid leukemia patients, the increased

peripheral blood mononuclear cell SSAT activity did not correlate with the white blood cell

count. Furthermore, the follow-up samples from treated chronic myeloid leukemia (CML)

patients exhibited a normalized peripheral blood white blood cell count and additionally

normalized peripheral blood mononuclear cell SSAT activity. An earlier study by Janssen et

al (Janssen et al. 2005) has also pointed to a role for SSAT in myeloid leukemias as its

expression was shown to differ during the different stages of CML (being highest in the

chronic phase in comparison to the diagnosis or that in a blast crisis). Moreover, the

expression of SSAT has been shown to be super-induced in response of 12-0-

tetradecanoylphorpol-13-acetate (TPA) induced differentiation of human myeloblastic

leukemia cell line ML-1 (Wang et al. 1998). Interestingly, increased SSAT expression has

also been related to megakaryocyte malignancy in a study which characterized genes in the

transition phase of acute megakaryoblastic leukemia (AMKL), a form of acute myeloid

leukemia in children with Down syndrome (Lightfoot et al. 2004). Taken together, the

earlier studies and these present findings from mouse and human studies indicate that

increased SSAT activity is linked to myeloid and megakaryocyte differentiation.

Polyamines have been shown to play essential roles in the differentiation of many cell

types (Facchini et al. 2012; Pietila et al. 2005; Vuohelainen et al. 2010). In SSAT mice, the

accumulation of putrescine has been reported to disturb the differentiation of keratinocytes

(Pietila et al. 2005). Also the hematopoietic cells of SSAT mice accumulated high levels of

putrescine whereas the levels of spermidine and spermine were reduced. Despite the

marked changes in the polyamine levels of hematopoietic cells, the polyamines do not seem

to substantially affect hematopoietic cell differentiation or the hematopoietic phenotype of

SSAT mice. Firstly, in a preliminary study, where wild-type and SSAT mice were treated

for three months with 2% difluoromethylornithine (DFMO, an ODC inhibitor) to decrease

the biosynthesis of polyamines, there were no changes detected in blood counts or bone

marrow cell counts, i.e. SSAT mice still exhibited neutrophilia as compared to wild-type

mice (unpublished data). However, DFMO treatment did reduce the levels of putrescine

35

and spermidine as well as the activity of SSAT in bone marrow cells of both genotypes.

Nonetheless, the SSAT activity of the cells of SSAT mice remained higher than that of wild-

type mice. Secondly, the blood counts and spleen weights of SSATKO mice were evaluated

but these mice did not exhibit any notable hematopoietic phenotype despite the alterations

in their hematopoietic cell polyamine levels (decreased putrescine and increased

spermidine concentrations, unpublished data). Thus, these results suggest that increased

SSAT activity influences the myeloproliferation in SSAT mice which is in line with the

present findings from studies of human leukemia samples described in earlier chapter.

SSAT has been reported to possess also other functions in addition to regulation of

cellular polyamine levels. For example, SSAT is able to bind integrin α9β1 and binding of

SSAT with integrin α9β1 could potentially influence the differentiation of hematopoietic

cells of SSAT mice as increased SSAT activity has been shown to enhance cell migration

through binding of this integrin (Chen et al. 2004). Integrin α9β1 is widely expressed in

many cell types, including neutrophils and hematopoietic stem cells (Grassinger et al. 2009;

Hoye et al. 2012). Mice lacking integrin α9β1 have been shown to exhibit a dramatic

impairment in neutrophil differentiation due to a defect in granulocyte colony-stimulating

factor (G-CSF) mediated signaling (Chen et al. 2006). The numbers of granulocyte precursor

cells and mature neutrophils are reduced in these mice. The results of Chen et al (2006),

however, indicate that SSAT binding does not affect the interaction of integrin and G-CSF.

Preliminary data from granulocytic cells of SSAT mice indicated that apoptosis of these

cells seemed to be decreased as compared to wild-type granulocytes (unpublished data).

Interestingly, in addition to playing a role in migration and differentiation, α9β1 is known

to regulate cell survival of neutrophils by inhibiting apoptosis through vascular cell

adhesion protein 1 (VCAM-1) binding (Ross et al. 2006). Thus, it is plausible that

hematopoietic phenotype of SSAT mice is partly influenced by the interplay between

integrin α9β1 and enhanced SSAT activity either through increased migration potential or

decreased apoptosis.

The enhanced catabolism in hematopoietic cells of SSAT mice enhanced the whole

polyamine metabolic cycle as, in addition to increased SSAT activity, also the ODC activity

was increased in the cells. The enhanced polyamine cycle could influence the availability of

metabolites, such as acetyl-CoA, which are shared with other metabolic pathways and in

this way it could affect hematopoietic cell differentiation (Jell et al. 2007; Kee et al. 2004a;

Pegg 2008). The consumption of acetyl-coA by SSAT could potentially interfere with the

acetylation processes conducted by histone acetyltransferases. However, it was found that

the increased activity of SSAT did not decrease the acetylation status of H3 lysine 9/14 in

bone marrow cells of SSAT overexpressing mice but rather increased it slightly (III). The

protein level of histone deacetylase 1 (HDAC1), was also increased in bone marrow cells of

SSAT mice compared to wild-type mice and the cells did show slight changes in their

histone methylation profile. Additionally, the myeloproliferative phenotype of SSAT mice

was attenuated when they were exposed to decitabine, a DNA methyltransferase drug that

is in clinical use. These data indicate that the myeloproliferation found in SSAT

overexpressing mice is related to epigenetic changes in the hematopoietic cells.

The enhanced polyamine cycle and concomitantly the increased acetylpolyamine oxidase

activity lead to the production of ROS which could potentially increase the level of

oxidative stress in SSAT mice. As a matter of fact, recently our group reported mice over-

expressing SSAT under the control of a metallothionein promoter (MT-SSAT mice) had an

36

increased cellular protein carbonyl content which was interpreted as an indication of

enhanced oxidative stress (Cerrada-Gimenez et al. 2011). Additionally, overall MT-SSAT

mice have a very similar phenotype to the SSAT mice used in the present experiments,

including similar changes in their blood cell count (unpublished data). Interestingly, ROS

have been implicated in hematopoietic malignancies as there is evidence for the presence of

chronic oxidative stress in chronic myeloid leukemia (CML) and acute myeloid leukemia

(AML) (Ahmad et al. 2008; Sallmyr et al. 2008). Furthermore, in normal hematopoiesis,

ROS are indicated to have signaling functions being linked especially to differentiation of

myeloid lineage cells, e.g. ROS are involved in promoting differentiation of Drosophila

hematopoietic cells akin to the mammalian myeloid progenitors (Owusu-Ansah and

Banerjee 2009). In addition, in murine myeloid progenitors, the ROS level has been shown

to be higher than that of hematopoietic stem cells and increased levels of intracellular ROS

in hematopoietic cells led to a myeloproliferative phenotype in mice which had a

conditional deletion of all FoxO isoforms (Tothova et al. 2007). In addition to differentiation

of myeloid cells, ROS have been shown to contribute to the lineage commitment of

megakaryocytes (Eliades et al. 2012; Sardina et al. 2010). Thus, increased oxidative stress, if

present in SSAT mice, could represent a possible mechanism to account the increased

myeloproliferation seen in these mice.

The bone marrow microenvironment is implicated to be associated with myeloid lineage

commitment of hematopoietic cells. In mouse models it has been shown that the bone

marrow microenvironment contributes to the development of myeloproliferation (Askmyr

et al. 2011; Walkley et al. 2007). Moreover, humans with myeloid diseases suffer from

related bone defects. However, the exact cell type within the microenvironment influencing

the myeloproliferation is not known in either case. The key component supporting HSC,

however, is known to be the osteoblastic cell (Calvi et al. 2003; Zhang et al. 2003). The first

experiments highlighting the importance of osteoblasts in HSC maintenance was conducted

with mice having a conditional inactivation of bone morphogenetic protein receptor type

IA (BMPRIA) (Calvi et al. 2003). These mice show, similarly to the situation in SSAT mice,

an increase in their LT-HSC numbers (II) which was evoked by an increase in the numbers

of early osteoblastic cells. Furthermore, a subsequent study by Raaijmakers et al

(Raaijmakers et al. 2010; Zhang et al. 2003) emphasized the importance of osteoprogenitors

in sustaining hematopoiesis. Interestingly, although osteoblasts of SSAT mice had an

impaired osteogenic potential, the serum concentration of a bone formation marker PINP

was increased, thus, indicating that the number of osteoblastic cells was increased in vivo in

SSAT mice. In support of this proposal, SSAT mice had also an increased number of

trabeculae which are the main sites for osteoblastic cells. SSAT HSCs showed increase in

proliferation rate compared to wild-type HSCs and decrease in expression of PU.1 which is

not only a differentiation marker but also a regulator of HSC maintenance (Iwasaki et al.

2005b). However, no changes were observed between wild-type and SSAT mice in other

self-renewal markers, GFI, BMI, GATA-2 or HOXB4, or in the proportion of apoptotic

HSCs. Thus, the expansion of the HSC pool in SSAT mice was not due to promotion of self-

renewal or to a block of apoptosis. All of these findings indicate that it is the osteoblastic

cells, rather than some intrinsic mechanisms which are likely to be responsible for the

increase in HSC number in SSAT mice. Furthermore, osteoblasts may take part also in the

regulation of lineage commitment in these mice.

37

IV Bone remodeling and structure in SSAT mice

SSAT overexpression elicited striking changes in the structure of bones in SSAT mice.

Outwardly the most apparent skeletal change was the hunched back. The long bones of

SSAT mice were larger in perimeter and the cortex became strikingly thin with age. The

bones of old SSAT mice snapped more easily than those of wild-type or SSATKO mice

when subjected to compression. The striking diminution of cortex explains the fragility to

compression. However, SSAT bones tolerated bending slightly better than wild-type or

SSATKO mice, which is understandable as the cortical bone of SSAT mice was larger in the

perimeter. SSAT osteoblasts were indicated to have a defect in the mineralization steps of

bone formation. However, there were no differences in the total bone mineral content of old

wild-type, SSAT and SSATKO mice but since the bones of SSAT mice were of a different

size than those of wild-type or SSATKO mice and the bone volume (BV) was increased in

these mice, there may be differences in the relative mineral density between the genotypes.

Thereby, since the bone mineral density of SSAT mice could not be confirmed, the bone

phenotype of these mice could not be designated as osteopenic/osteoporotic.

The osteoblastogenesis of SSAT mice was cell-autonomously impaired as the activity of

alkaline phosphatase (ALP), an enzyme required for generation of inorganic phosphate for

hydroxyapatite crystallization, was decreased in in vitro differentiated SSAT osteoblasts.

Additionally, calcium nodules were nearly absent and there was reduced gene expression

of late osteogenic markers. The osteoblasts of mice deficient for SSAT showed opposite

features, thus, supporting the view that the level of SSAT activity affected

osteoblastogenesis. Serum markers supported the in vitro results of impaired mineralization

steps of bone formation in SSAT mice as there was a reduction in the concentration of

osteocalcin, a protein which binds the hydroxyapatite mineral of bone matrix. However,

even though the maturation of osteoblasts was impaired, the circulating PINP was slightly

increased. PINP is a byproduct of collagen cleavage and thus a marker of bone formation

rate. The increased activity of PINP, thereby, indicated the numbers of osteoblastic cells

were increased in SSAT mice. SSAT osteoclasts displayed no notable changes in their

number in cell culture, but the reduced serum tartrate-resistant acid phosphatase

(TRAcP5b) concentration indicated that their number in vivo was decreased (Alatalo et al.

2004). Despite the decreased number of osteoclasts, their activity, as measured by a marker

of collagen degradation (CTX), remained comparable between wild-type and SSAT mice.

This indicated that the relative activity of osteoclasts (activity per osteoclast) was increased

in SSAT mice. The expression of the master transcriptional regulator of osteoclastogenesis,

NFATc1, was increased in SSAT osteoclasts. However, this was not reflected in the

expressions of either TRAcP or cathepsin K (CTSK). The lack of effect on osteoclastogenic

markers may have been due to the early time-point used in the experiment. Taken together,

the bone phenotype of SSAT mice resulted, for the most part, from an impaired function of

osteoblasts.

A recent study has shown that polyamines enhance osteoblastogenesis (Lee et al. 2013).

However in SSAT mice, although the osteoblastic concentration of spermidine was

reduced, the mechanism leading to defective osteoblastogenesis appeared to be related to

the induction of SSAT enzyme activity. First of all, the treatment of SSAT osteoblasts with a

spermidine analogue did not improve osteoblastogenesis in the SSAT mice. Secondly,

SSATKO osteoblasts showed a significantly higher osteoblastogenic potential than that of

SSAT mice, even though their polyamine levels did not dramatically differ from each other.

38

Finally, the osteoblastogenesis in the wild-type osteoblasts was decreased to the level of

SSAT osteoblasts in response to addition of α-methylspermidine to the culture media and

the common feature with the analogue-treated wild-type and SSAT osteoblasts was the

high enzymatic activity of SSAT. In contrast to the situation in hematopoietic cells, the

increased SSAT activity did not affect the acetylation status of histone protein 3 in the

osteoblasts of SSAT overexpressing mice (data not shown). Thus, the effect of polyamine

catabolism on osteoblastogenesis could be mediated through increased oxidative stress. The

MT-SSAT mice, which have been reported to have increased oxidative stress, express also

increased levels of p53 and age prematurely (Cerrada-Gimenez et al. 2011). Similarly to

SSAT mice, MT-SSAT mice display skeletal changes such as kyphosis (unpublished data).

Age-related changes in the bone phenotype, such as expansion of marrow space and

thinning of cortex, are known to result from increased oxidative stress in mice (Almeida et

al. 2007a; Levasseur et al. 2003). Aging mice suffer defects in osteoblastogenesis and,

additionally, the number of osteoclasts declines with age (Almeida et al. 2007b).

Additionally in humans, osteoblastogenic potential of mesenchymal stromal cells (MSCs) is

reduced with age (D'Ippolito et al. 1999). Moreover, oxidative stress has been demonstrated

to impair osteoblastogenesis also in rabbit MSCs and gamma-glutamyl transpeptidase

(GGT) deficient mice (Bai et al. 2004; Levasseur et al. 2003). Therefore, premature aging and

oxidative stress would seem to be plausible explanations for the changes seen in

osteoblastogenesis and in bone phenotype of SSAT mice.

39

7 Summary and conclusions

Not much is known about the role of polyamines, let alone about SSAT, in the immune

response, hematopoiesis and bone formation. These present studies have shed some light

on the role of enhanced polyamine catabolism in these processes. The results demonstrated

that it was the presence of enhanced polyamine catabolism, rather than the polyamines

themselves, which disturbed bone formation in SSAT overexpressing mice. Aberrant bone

formation evoked changes in the bone marrow microenvironment which, together with

intrinsic SSAT overexpression of hematopoietic cells, resulted in a myeloproliferative

disease in these mice. The observation that SSAT activity was associated with the white

blood cell count in human myeloid leukemias is further support for the view that SSAT

activity is connected to myeloid cell development.

I SSAT mice displayed no difference in their response to endotoxic shock with respect to

survival or symptoms. However, at the molecular level, SSAT mice showed a slightly

enhanced anti-inflammatory response. The basal levels of serum cytokines and acute-phase

protein expressions of SSAT mice were comparable to those in their wild-type littermates

which indicated SSAT mice did not suffer from a systemic chronic inflammation in the

basal state.

II The investigation of hematopoietic phenotype of SSAT mice revealed an enhanced

blood leukocyte count dominated by mature neutrophils at the expense of lymphocytes.

The blood platelet number was also increased whereas the red blood cell count decreased

with age, causing anemia. In addition, the spleens of SSAT mice were larger than those of

their wild-type counterparts and the bone marrow cellularity was increased revealing the

presence of enhanced myelopoiesis and thrombocytopoiesis. The numbers of long-term

hematopoietic stem cells and granulocyte-macrophage progenitors were increased in the

bone marrows of SSAT mice whereas the number of megakaryocyte-erythrocyte

progenitors was reduced. Altogether, the hematopoietic phenotype of SSAT mice fulfilled

the criteria of mouse myeloproliferative disease. The myeloproliferative phenotype of SSAT

mice resulted from both the intrinsic SSAT overexpression and from microenvironmental

factors. The myeloproliferative phenotype of SSAT mice indicated that the enhanced SSAT

activity was participating in myeloid differentiation.

III Patients with chronic myeloid leukemia, acute myeloid leukemia and acute lymphoid

leukemia showed increased levels of spermidine and spermine and enhanced SSAT activity

in their peripheral blood mononuclear cells. The increased SSAT activity was associated

with the increased number of white blood cells in myeloid leukemias but not in lymphoid

leukemia. This supported the findings from SSAT mice that SSAT activity was associated

with myeloproliferation. The myeloproliferation of these mice was considered to be

connected to epigenetic factors as the SSAT mice showed a differential response to human

leukemia drugs affecting epigenetics and the acetylation and methylation patterns of bone

marrow cells differed from those found in their wild-type controls.

IV The bones of SSAT mice broke more easily than those of wild-type mice when

compressed. The long bones of SSAT mice were enlarged at the perimeter yet had a

strikingly thinned cortical wall. The thickness of the trabeculae was also decreased in SSAT

40

mice but their number was increased. Osteoblastogenesis was cell-autonomously impaired

in SSAT mice. Nevertheless, there appeared to be a greater number of premature

osteoblasts. Altogether, the cellular and structural changes in the bones meant that there

was a larger niche for hematopoietic cells. Thus, the bone phenotype studies supported the

view that the myeloproliferation of SSAT mice was partly due to bone marrow

microenvironmental factors. The study also indicated that SSAT activity impaired

osteoblastogenesis through some mechanism other than depletion of polyamine levels. This

mechanism could potentially be through excess production of ROS.

These findings increase our understanding of the role of polyamine metabolism in

hematopoiesis and bone remodeling. Together with earlier studies, these present findings

emphasize the important role of SSAT in myeloid cell differentiation. In addition, these

studies contribute to the body of research investigating the interplay between

hematopoietic cells and bone microenvironment. Importantly, they also highlight the

contribution of the catabolic part of the polyamine cycle in pathophysiological processes. In

particular, highlighting the possibility that functions other than polyamine depletion may

be responsible for the disturbed cellular homeostasis in bone forming cells and perhaps also

in hematopoietic cells.

41

8 References

Adams GB, Chabner KT, Alley IR, Olson DP, Szczepiorkowski ZM, Poznansky MC, Kos CH,

Pollak MR, Brown EM, Scadden DT (2006) Stem cell engraftment at the endosteal niche is specified

by the calcium-sensing receptor. Nature 439:599-603.

Adolfsson J, Mansson R, Buza-Vidas N, Hultquist A, Liuba K, Jensen CT, Bryder D, Yang L, Borge

OJ, Thoren LA, Anderson K, Sitnicka E, Sasaki Y, Sigvardsson M, Jacobsen SE (2005)

Identification of Flt3+ lympho-myeloid stem cells lacking erythro-megakaryocytic potential a

revised road map for adult blood lineage commitment. Cell 121:295-306.

Adolfsson J, Borge OJ, Bryder D, Theilgaard-Monch K, Astrand-Grundstrom I, Sitnicka E, Sasaki

Y, Jacobsen SE (2001) Upregulation of Flt3 expression within the bone marrow Lin(-)Sca1(+)c-

kit(+) stem cell compartment is accompanied by loss of self-renewal capacity. Immunity 15:659-669.

Ahmad R, Tripathi AK, Tripathi P, Singh S, Singh R, Singh RK (2008) Malondialdehyde and protein

carbonyl as biomarkers for oxidative stress and disease progression in patients with chronic myeloid

leukemia. In Vivo 22:525-528.

Akashi K, Traver D, Miyamoto T, Weissman IL (2000) A clonogenic common myeloid progenitor

that gives rise to all myeloid lineages. Nature 404:193-197.

Alatalo SL, Ivaska KK, Waguespack SG, Econs MJ, Vaananen HK, Halleen JM (2004) Osteoclast-

derived serum tartrate-resistant acid phosphatase 5b in Albers-Schonberg disease (type II autosomal

dominant osteopetrosis). Clin Chem 50:883-890.

Alhonen L, Parkkinen JJ, Keinanen T, Sinervirta R, Herzig KH, Janne J (2000) Activation of

polyamine catabolism in transgenic rats induces acute pancreatitis. Proc Natl Acad Sci U S A

97:8290-8295.

Almeida M, Han L, Martin-Millan M, O'Brien CA, Manolagas SC (2007a) Oxidative stress

antagonizes Wnt signaling in osteoblast precursors by diverting beta-catenin from T cell factor- to

forkhead box O-mediated transcription. J Biol Chem 282:27298-27305.

Almeida M, Han L, Martin-Millan M, Plotkin LI, Stewart SA, Roberson PK, Kousteni S, O'Brien

CA, Bellido T, Parfitt AM, Weinstein RS, Jilka RL, Manolagas SC (2007b) Skeletal involution by

age-associated oxidative stress and its acceleration by loss of sex steroids. J Biol Chem 282:27285-

27297.

Arena JF, Schwartz C, Ouzts L, Stevenson R, Miller M, Garza J, Nance M, Lubs H (1996) X-linked

mental retardation with thin habitus, osteoporosis, and kyphoscoliosis: linkage to Xp21.3-p22.12.

Am J Med Genet 64:50-58.

Argiropoulos B, Humphries RK (2007) Hox genes in hematopoiesis and leukemogenesis. Oncogene

26:6766-6776.

42

Arinobu Y, Iwasaki H, Gurish MF, Mizuno S, Shigematsu H, Ozawa H, Tenen DG, Austen KF,

Akashi K (2005) Developmental checkpoints of the basophil/mast cell lineages in adult murine

hematopoiesis. Proc Natl Acad Sci U S A 102:18105-18110.

Askmyr M, Quach J, Purton LE (2011) Effects of the bone marrow microenvironment on

hematopoietic malignancy. Bone 48:115-120.

Babbar N, Murray-Stewart T, Casero RA,Jr (2007) Inflammation and polyamine catabolism: the

good, the bad and the ugly. Biochem Soc Trans 35:300-304.

Bai XC, Lu D, Bai J, Zheng H, Ke ZY, Li XM, Luo SQ (2004) Oxidative stress inhibits osteoblastic

differentiation of bone cells by ERK and NF-kappaB. Biochem Biophys Res Commun 314:197-207.

Bardocz S (1993) The role of dietary polyamines. Eur J Clin Nutr 47:683-690.

Becerra-Solano LE, Butler J, Castaneda-Cisneros G, McCloskey DE, Wang X, Pegg AE, Schwartz

CE, Sanchez-Corona J, Garcia-Ortiz JE (2009) A missense mutation, p.V132G, in the X-linked

spermine synthase gene (SMS) causes Snyder-Robinson syndrome. Am J Med Genet A 149A:328-

335.

Beerman I, Bhattacharya D, Zandi S, Sigvardsson M, Weissman IL, Bryder D, Rossi DJ (2010a)

Functionally distinct hematopoietic stem cells modulate hematopoietic lineage potential during aging

by a mechanism of clonal expansion. Proc Natl Acad Sci U S A 107:5465-5470.

Beerman I, Maloney WJ, Weissmann IL, Rossi DJ (2010b) Stem cells and the aging hematopoietic

system. Curr Opin Immunol 22:500-506.

Bergeron C, Bansard JY, Le Moine P, Bouet F, Goasguen JE, Moulinoux JP, Le Gall E, Catros-

Quemener V (1997) Erythrocyte spermine levels: a prognostic parameter in childhood common acute

lymphoblastic leukemia. Leukemia 11:31-36.

Bernacki RJ, Oberman EJ, Seweryniak KE, Atwood A, Bergeron RJ, Porter CW (1995) Preclinical

antitumor efficacy of the polyamine analogue N1, N11-diethylnorspermine administered by multiple

injection or continuous infusion. Clin Cancer Res 1:847-857.

Bettuzzi S, Davalli P, Astancolle S, Pinna C, Roncaglia R, Boraldi F, Tiozzo R, Sharrard M, Corti A

(1999) Coordinate changes of polyamine metabolism regulatory proteins during the cell cycle of

normal human dermal fibroblasts. FEBS Lett 446:18-22.

Bewley MC, Graziano V, Jiang J, Matz E, Studier FW, Pegg AE, Coleman CS, Flanagan JM (2006)

Structures of wild-type and mutant human spermidine/spermine N1-acetyltransferase, a potential

therapeutic drug target. Proc Natl Acad Sci U S A 103:2063-2068.

Bhatia SK, Tygrett LT, Grabstein KH, Waldschmidt TJ (1995) The effect of in vivo IL-7 deprivation

on T cell maturation. J Exp Med 181:1399-1409.

Bilezikian JP, Raisz LG, Martin TJ (2008) Principles of bone biology Vol 1.

Blank U, Karlsson G, Karlsson S (2008) Signaling pathways governing stem-cell fate. Blood

111:492-503.

Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Muller R (2010) Guidelines for

assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res

25:1468-1486.

43

Byers TL, Pegg AE (1989) Properties and physiological function of the polyamine transport system.

Am J Physiol 257:C545-53.

Calvi LM, Adams GB, Weibrecht KW, Weber JM, Olson DP, Knight MC, Martin RP, Schipani E,

Divieti P, Bringhurst FR, Milner LA, Kronenberg HM, Scadden DT (2003) Osteoblastic cells

regulate the haematopoietic stem cell niche. Nature 425:841-846.

Carlesso N, Cardoso AA (2010) Stem cell regulatory niches and their role in normal and malignant

hematopoiesis. Curr Opin Hematol 17:281-286.

Casero RA, Pegg AE (2009) Polyamine catabolism and disease. Biochem J 421:323-338.

Casero RA,Jr, Pegg AE (1993) Spermidine/spermine N1-acetyltransferase--the turning point in

polyamine metabolism. FASEB J 7:653-661.

Cason AL, Ikeguchi Y, Skinner C, Wood TC, Holden KR, Lubs HA, Martinez F, Simensen RJ,

Stevenson RE, Pegg AE, Schwartz CE (2003) X-linked spermine synthase gene (SMS) defect: the

first polyamine deficiency syndrome. Eur J Hum Genet 11:937-944.

Cedar H, Bergman Y (2011) Epigenetics of haematopoietic cell development. Nat Rev Immunol

11:478-488.

Cerrada-Gimenez M, Pietila M, Loimas S, Pirinen E, Hyvonen MT, Keinanen TA, Janne J, Alhonen

L (2011) Continuous oxidative stress due to activation of polyamine catabolism accelerates aging

and protects against hepatotoxic insults. Transgenic Res 20:387-396.

Chambers TJ (2000) Regulation of the differentiation and function of osteoclasts. J Pathol 192:4-13.

Chen C, Huang X, Atakilit A, Zhu QS, Corey SJ, Sheppard D (2006) The Integrin alpha9beta1

contributes to granulopoiesis by enhancing granulocyte colony-stimulating factor receptor signaling.

Immunity 25:895-906.

Chen C, Young BA, Coleman CS, Pegg AE, Sheppard D (2004) Spermidine/spermine N1-

acetyltransferase specifically binds to the integrin alpha9 subunit cytoplasmic domain and enhances

cell migration. J Cell Biol 167:161-170.

Clarke B (2008) Normal bone anatomy and physiology. Clin J Am Soc Nephrol 3 Suppl 3:S131-9.

Cohen SS (1998) A Guide to the Polyamines. Oxford University Press, New York.

Coleman CS, Pegg AE, Megosh LC, Guo Y, Sawicki JA, O'Brien TG (2002) Targeted expression of

spermidine/spermine N1-acetyltransferase increases susceptibility to chemically induced skin

carcinogenesis. Carcinogenesis 23:359-364.

Coleman CS, Pegg AE (1997) Proteasomal degradation of spermidine/spermine N1-acetyltransferase

requires the carboxyl-terminal glutamic acid residues. J Biol Chem 272:12164-12169.

Coleman CS, Stanley BA, Viswanath R, Pegg AE (1994) Rapid exchange of subunits of mammalian

ornithine decarboxylase. J Biol Chem 269:3155-3158.

Crispino JD (2005) GATA1 in normal and malignant hematopoiesis. Semin Cell Dev Biol 16:137-

147.

44

Dahl R, Walsh JC, Lancki D, Laslo P, Iyer SR, Singh H, Simon MC (2003) Regulation of

macrophage and neutrophil cell fates by the PU.1:C/EBPalpha ratio and granulocyte colony-

stimulating factor. Nat Immunol 4:1029-1036.

Dakic A, Metcalf D, Di Rago L, Mifsud S, Wu L, Nutt SL (2005) PU.1 regulates the commitment of

adult hematopoietic progenitors and restricts granulopoiesis. J Exp Med 201:1487-1502.

Davis RH, Morris DR, Coffino P (1992) Sequestered end products and enzyme regulation: the case

of ornithine decarboxylase. Microbiol Rev 56:280-290.

de Alencastro G, McCloskey DE, Kliemann SE, Maranduba CM, Pegg AE, Wang X, Bertola DR,

Schwartz CE, Passos-Bueno MR, Sertie AL (2008) New SMS mutation leads to a striking reduction

in spermine synthase protein function and a severe form of Snyder-Robinson X-linked recessive

mental retardation syndrome. J Med Genet 45:539-543.

deHart GW, Jin T, McCloskey DE, Pegg AE, Sheppard D (2008) The alpha9beta1 integrin enhances

cell migration by polyamine-mediated modulation of an inward-rectifier potassium channel. Proc

Natl Acad Sci U S A 105:7188-7193.

DeKoter RP, Singh H (2000) Regulation of B lymphocyte and macrophage development by graded

expression of PU.1. Science 288:1439-1441.

Della Ragione F, Pegg AE (1983) Studies of the specificity and kinetics of rat liver

spermidine/spermine N1-acetyltransferase. Biochem J 213:701-706.

Dennis JE, Merriam A, Awadallah A, Yoo JU, Johnstone B, Caplan AI (1999) A quadripotential

mesenchymal progenitor cell isolated from the marrow of an adult mouse. J Bone Miner Res 14:700-

709.

D'Ippolito G, Schiller PC, Ricordi C, Roos BA, Howard GA (1999) Age-related osteogenic potential

of mesenchymal stromal stem cells from human vertebral bone marrow. J Bone Miner Res 14:1115-

1122.

Donevan SD, Rogawski MA (1995) Intracellular polyamines mediate inward rectification of Ca(2+)-

permeable alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors. Proc Natl Acad

Sci U S A 92:9298-9302.

Ducy P, Starbuck M, Priemel M, Shen J, Pinero G, Geoffroy V, Amling M, Karsenty G (1999) A

Cbfa1-dependent genetic pathway controls bone formation beyond embryonic development. Genes

Dev 13:1025-1036.

Dumble M, Moore L, Chambers SM, Geiger H, Van Zant G, Goodell MA, Donehower LA (2007)

The impact of altered p53 dosage on hematopoietic stem cell dynamics during aging. Blood

109:1736-1742.

Edwards CM, Zhuang J, Mundy GR (2008) The pathogenesis of the bone disease of multiple

myeloma. Bone 42:1007-1013.

Eliades A, Matsuura S, Ravid K (2012) Oxidases and reactive oxygen species during hematopoiesis:

a focus on megakaryocytes. J Cell Physiol 227:3355-3362.

Eriksen EF (2010) Cellular mechanisms of bone remodeling. Rev Endocr Metab Disord 11:219-227.

45

Facchini A, Borzi RM, Olivotto E, Platano D, Pagani S, Cetrullo S, Flamigni F (2012) Role of

polyamines in hypertrophy and terminal differentiation of osteoarthritic chondrocytes. Amino Acids

42:667-678.

Fredericq E, Hacha R, Colson P, Houssier C (1991) Condensation and precipitation of chromatin by

multivalent cations. J Biomol Struct Dyn 8:847-865.

Friedman AD (2007) Transcriptional control of granulocyte and monocyte development. Oncogene

26:6816-6828.

Frisch BJ, Ashton JM, Xing L, Becker MW, Jordan CT, Calvi LM (2012) Functional inhibition of

osteoblastic cells in an in vivo mouse model of myeloid leukemia. Blood 119:540-550.

Ganss B, Kim RH, Sodek J (1999) Bone sialoprotein. Crit Rev Oral Biol Med 10:79-98.

Gaur T, Lengner CJ, Hovhannisyan H, Bhat RA, Bodine PV, Komm BS, Javed A, van Wijnen AJ,

Stein JL, Stein GS, Lian JB (2005) Canonical WNT signaling promotes osteogenesis by directly

stimulating Runx2 gene expression. J Biol Chem 280:33132-33140.

Gimelli G, Giglio S, Zuffardi O, Alhonen L, Suppola S, Cusano R, Lo Nigro C, Gatti R, Ravazzolo

R, Seri M (2002) Gene dosage of the spermidine/spermine N(1)-acetyltransferase ( SSAT) gene with

putrescine accumulation in a patient with a Xp21.1p22.12 duplication and keratosis follicularis

spinulosa decalvans (KFSD). Hum Genet 111:235-241.

Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC (1996) Isolation and functional

properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 183:1797-1806.

Graf T, Enver T (2009) Forcing cells to change lineages. Nature 462:587-594.

Grassinger J, Haylock DN, Storan MJ, Haines GO, Williams B, Whitty GA, Vinson AR, Be CL, Li

S, Sorensen ES, Tam PP, Denhardt DT, Sheppard D, Choong PF, Nilsson SK (2009) Thrombin-

cleaved osteopontin regulates hemopoietic stem and progenitor cell functions through interactions

with alpha9beta1 and alpha4beta1 integrins. Blood 114:49-59.

Ha HC, Sirisoma NS, Kuppusamy P, Zweier JL, Woster PM, Casero RA,Jr (1998a) The natural

polyamine spermine functions directly as a free radical scavenger. Proc Natl Acad Sci U S A

95:11140-11145.

Ha HC, Sirisoma NS, Kuppusamy P, Zweier JL, Woster PM, Casero RA,Jr (1998b) The natural

polyamine spermine functions directly as a free radical scavenger. Proc Natl Acad Sci U S A

95:11140-11145.

Heino TJ, Hentunen TA (2008) Differentiation of osteoblasts and osteocytes from mesenchymal

stem cells. Curr Stem Cell Res Ther 3:131-145.

Hock H, Hamblen MJ, Rooke HM, Schindler JW, Saleque S, Fujiwara Y, Orkin SH (2004) Gfi-1

restricts proliferation and preserves functional integrity of haematopoietic stem cells. Nature

431:1002-1007.

Hoesel LM, Neff TA, Neff SB, Younger JG, Olle EW, Gao H, Pianko MJ, Bernacki KD, Sarma JV,

Ward PA (2005) Harmful and protective roles of neutrophils in sepsis. Shock 24:40-47.

Holst CM, Nevsten P, Johansson F, Carlemalm E, Oredsson SM (2008) Subcellular distribution of

spermidine/spermine N1-acetyltransferase. Cell Biol Int 32:39-47.

46

Holtta E (1977) Oxidation of spermidine and spermine in rat liver: purification and properties of

polyamine oxidase. Biochemistry 16:91-100.

Hougaard DM, Bolund L, Fujiwara K, Larsson LI (1987) Endogenous polyamines are intimately

associated with highly condensed chromatin in vivo. A fluorescence cytochemical and

immunocytochemical study of spermine and spermidine during the cell cycle and in reactivated

nuclei. Eur J Cell Biol 44:151-155.

Hoye AM, Couchman JR, Wewer UM, Fukami K, Yoneda A (2012) The newcomer in the integrin

family: integrin alpha9 in biology and cancer. Adv Biol Regul 52:326-339.

Hyvonen MT, Merentie M, Uimari A, Keinanen TA, Janne J, Alhonen L (2007) Mechanisms of

polyamine catabolism-induced acute pancreatitis. Biochem Soc Trans 35:326-330.

Hyvonen T, Seiler N, Persson L (1994) Characterization of a COS cell line deficient in polyamine

transport. Biochim Biophys Acta 1221:279-285.

Hyvonen T, Keinanen TA, Khomutov AR, Khomutov RM, Eloranta TO (1992) Monitoring of the

uptake and metabolism of aminooxy analogues of polyamines in cultured cells by high-performance

liquid chromatography. J Chromatogr 574:17-21.

Igarashi K, Kashiwagi K (2010) Modulation of cellular function by polyamines. Int J Biochem Cell

Biol 42:39-51.

Ikeguchi Y, Bewley MC, Pegg AE (2006) Aminopropyltransferases: function, structure and genetics.

J Biochem 139:1-9.

Ikuta K, Weissman IL (1992) Evidence that hematopoietic stem cells express mouse c-kit but do not

depend on steel factor for their generation. Proc Natl Acad Sci U S A 89:1502-1506.

Ito K, Hirao A, Arai F, Matsuoka S, Takubo K, Hamaguchi I, Nomiyama K, Hosokawa K, Sakurada

K, Nakagata N, Ikeda Y, Mak TW, Suda T (2004) Regulation of oxidative stress by ATM is required

for self-renewal of haematopoietic stem cells. Nature 431:997-1002.

Iwasaki H, Akashi K (2007a) Myeloid lineage commitment from the hematopoietic stem cell.

Immunity 26:726-740.

Iwasaki H, Akashi K (2007b) Hematopoietic developmental pathways: on cellular basis. Oncogene

26:6687-6696.

Iwasaki H, Mizuno S, Mayfield R, Shigematsu H, Arinobu Y, Seed B, Gurish MF, Takatsu K,

Akashi K (2005a) Identification of eosinophil lineage-committed progenitors in the murine bone

marrow. J Exp Med 201:1891-1897.

Iwasaki H, Somoza C, Shigematsu H, Duprez EA, Iwasaki-Arai J, Mizuno S, Arinobu Y, Geary K,

Zhang P, Dayaram T, Fenyus ML, Elf S, Chan S, Kastner P, Huettner CS, Murray R, Tenen DG,

Akashi K (2005b) Distinctive and indispensable roles of PU.1 in maintenance of hematopoietic stem

cells and their differentiation. Blood 106:1590-1600.

Jamsa T, Viluksela M, Tuomisto JT, Tuomisto J, Tuukkanen J (2001) Effects of 2,3,7,8-

tetrachlorodibenzo-p-dioxin on bone in two rat strains with different aryl hydrocarbon receptor

structures. J Bone Miner Res 16:1812-1820.

47

Janne J, Alhonen L, Pietila M, Keinanen TA, Uimari A, Hyvonen MT, Pirinen E, Jarvinen A (2006)

Genetic manipulation of polyamine catabolism in rodents. J Biochem 139:155-160.

Janne J, Williams-Ashman HG (1971) On the purification of L-ornithine decarboxylase from rat

prostate and effects of thiol compounds on the enzyme. J Biol Chem 246:1725-1732.

Janssen JJ, Klaver SM, Waisfisz Q, Pasterkamp G, de Kleijn DP, Schuurhuis GJ, Ossenkoppele GJ

(2005) Identification of genes potentially involved in disease transformation of CML. Leukemia

19:998-1004.

Jell J, Merali S, Hensen ML, Mazurchuk R, Spernyak JA, Diegelman P, Kisiel ND, Barrero C, Deeb

KK, Alhonen L, Patel MS, Porter CW (2007) Genetically altered expression of spermidine/spermine

N1-acetyltransferase affects fat metabolism in mice via acetyl-CoA. J Biol Chem 282:8404-8413.

Kameji T, Pegg AE (1987) Effect of putrescine on the synthesis of S-adenosylmethionine

decarboxylase. Biochem J 243:285-288.

Kankaanpaa J, Turunen SP, Moilanen V, Horkko S, Remes AM (2009) Cerebrospinal fluid

antibodies to oxidized LDL are increased in Alzheimer's disease. Neurobiol Dis 33:467-472.

Karsenty G (2000) Bone formation and factors affecting this process. Matrix Biol 19:85-89.

Katayama Y, Battista M, Kao WM, Hidalgo A, Peired AJ, Thomas SA, Frenette PS (2006) Signals

from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow.

Cell 124:407-421.

Kee K, Foster BA, Merali S, Kramer DL, Hensen ML, Diegelman P, Kisiel N, Vujcic S, Mazurchuk

RV, Porter CW (2004a) Activated polyamine catabolism depletes acetyl-CoA pools and suppresses

prostate tumor growth in TRAMP mice. J Biol Chem 279:40076-40083.

Kee K, Vujcic S, Merali S, Diegelman P, Kisiel N, Powell CT, Kramer DL, Porter CW (2004b)

Metabolic and antiproliferative consequences of activated polyamine catabolism in LNCaP prostate

carcinoma cells. J Biol Chem 279:27050-27058.

Kingsnorth AN, Wallace HM (1985) Elevation of monoacetylated polyamines in human breast

cancers. Eur J Cancer Clin Oncol 21:1057-1062.

Kingsnorth AN, Lumsden AB, Wallace HM (1984a) Polyamines in colorectal cancer. Br J Surg

71:791-794.

Kingsnorth AN, Wallace HM, Bundred NJ, Dixon JM (1984b) Polyamines in breast cancer. Br J

Surg 71:352-356.

Kogan SC, Ward JM, Anver MR, Berman JJ, Brayton C, Cardiff RD, Carter JS, de Coronado S,

Downing JR, Fredrickson TN, Haines DC, Harris AW, Harris NL, Hiai H, Jaffe ES, MacLennan IC,

Pandolfi PP, Pattengale PK, Perkins AS, Simpson RM, Tuttle MS, Wong JF, Morse HC,3rd,

Hematopathology subcommittee of the Mouse Models of Human Cancers Consortium (2002)

Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood

100:238-245.

Kohler A, Schmithorst V, Filippi MD, Ryan MA, Daria D, Gunzer M, Geiger H (2009) Altered

cellular dynamics and endosteal location of aged early hematopoietic progenitor cells revealed by

time-lapse intravital imaging in long bones. Blood 114:290-298.

48

Komori T (2003) Requisite roles of Runx2 and Cbfb in skeletal development. J Bone Miner Metab

21:193-197.

Kondo M, Weissman IL, Akashi K (1997) Identification of clonogenic common lymphoid

progenitors in mouse bone marrow. Cell 91:661-672.

Kopp HG, Avecilla ST, Hooper AT, Rafii S (2005) The bone marrow vascular niche: home of HSC

differentiation and mobilization. Physiology (Bethesda) 20:349-356.

Kular J, Tickner J, Chim SM, Xu J (2012) An overview of the regulation of bone remodelling at the

cellular level. Clin Biochem 45:863-873.

Lee MJ, Chen Y, Huang YP, Hsu YC, Chiang LH, Chen TY, Wang GJ (2013) Exogenous

polyamines promote osteogenic differentiation by reciprocally regulating osteogenic and adipogenic

gene expression. J Cell Biochem 114:2718-2728.

Lee SB, Park JH, Folk JE, Deck JA, Pegg AE, Sokabe M, Fraser CS, Park MH (2011) Inactivation of

eukaryotic initiation factor 5A (eIF5A) by specific acetylation of its hypusine residue by

spermidine/spermine acetyltransferase 1 (SSAT1). Biochem J 433:205-213.

Lee SB, Park JH, Woster PM, Casero RA,Jr, Park MH (2010) Suppression of exogenous gene

expression by spermidine/spermine N1-acetyltransferase 1 (SSAT1) cotransfection. J Biol Chem

285:15548-15556.

Leskela HV, Risteli J, Niskanen S, Koivunen J, Ivaska KK, Lehenkari P (2003) Osteoblast

recruitment from stem cells does not decrease by age at late adulthood. Biochem Biophys Res

Commun 311:1008-1013.

Levasseur R, Barrios R, Elefteriou F, Glass DA,2nd, Lieberman MW, Karsenty G (2003) Reversible

skeletal abnormalities in gamma-glutamyl transpeptidase-deficient mice. Endocrinology 144:2761-

2764.

Li CL, Johnson GR (1995) Murine hematopoietic stem and progenitor cells: I. Enrichment and

biologic characterization. Blood 85:1472-1479.

Li J (2011) Quiescence regulators for hematopoietic stem cell. Exp Hematol 39:511-520.

Lightfoot J, Hitzler JK, Zipursky A, Albert M, Macgregor PF (2004) Distinct gene signatures of

transient and acute megakaryoblastic leukemia in Down syndrome. Leukemia 18:1617-1623.

Liu W, Toyosawa S, Furuichi T, Kanatani N, Yoshida C, Liu Y, Himeno M, Narai S, Yamaguchi A,

Komori T (2001) Overexpression of Cbfa1 in osteoblasts inhibits osteoblast maturation and causes

osteopenia with multiple fractures. J Cell Biol 155:157-166.

Lyon MF, Scriver CR, Baker LR, Tenenhouse HS, Kronick J, Mandla S (1986) The Gy mutation:

another cause of X-linked hypophosphatemia in mouse. Proc Natl Acad Sci U S A 83:4899-4903.

Maatta JA, Buki KG, Gu G, Alanne MH, Vaaraniemi J, Liljenback H, Poutanen M, Harkonen P,

Vaananen K (2013) Inactivation of estrogen receptor alpha in bone-forming cells induces bone loss

in female mice. FASEB J 27:478-488.

Mackintosh CA, Pegg AE (2000) Effect of spermine synthase deficiency on polyamine biosynthesis

and content in mice and embryonic fibroblasts, and the sensitivity of fibroblasts to 1,3-bis-(2-

chloroethyl)-N-nitrosourea. Biochem J 351 Pt 2:439-447.

49

Mancini E, Sanjuan-Pla A, Luciani L, Moore S, Grover A, Zay A, Rasmussen KD, Luc S, Bilbao D,

O'Carroll D, Jacobsen SE, Nerlov C (2012) FOG-1 and GATA-1 act sequentially to specify

definitive megakaryocytic and erythroid progenitors. EMBO J 31:351-365.

Manz MG, Traver D, Miyamoto T, Weissman IL, Akashi K (2001) Dendritic cell potentials of early

lymphoid and myeloid progenitors. Blood 97:3333-3341.

Marie PJ (2008) Transcription factors controlling osteoblastogenesis. Arch Biochem Biophys

473:98-105.

Martin TJ, Sims NA (2005) Osteoclast-derived activity in the coupling of bone formation to

resorption. Trends Mol Med 11:76-81.

Maruyama Z, Yoshida CA, Furuichi T, Amizuka N, Ito M, Fukuyama R, Miyazaki T, Kitaura H,

Nakamura K, Fujita T, Kanatani N, Moriishi T, Yamana K, Liu W, Kawaguchi H, Nakamura K,

Komori T (2007) Runx2 determines bone maturity and turnover rate in postnatal bone development

and is involved in bone loss in estrogen deficiency. Dev Dyn 236:1876-1890.

Matsui I, Pegg AE (1981) Effect of inhibitors of protein synthesis on rat liver spermidine N-

acetyltransferase. Biochim Biophys Acta 675:373-378.

McKenzie JL, Takenaka K, Gan OI, Doedens M, Dick JE (2007) Low rhodamine 123 retention

identifies long-term human hematopoietic stem cells within the Lin-CD34+CD38- population. Blood

109:543-545.

McKercher SR, Torbett BE, Anderson KL, Henkel GW, Vestal DJ, Baribault H, Klemsz M, Feeney

AJ, Wu GE, Paige CJ, Maki RA (1996) Targeted disruption of the PU.1 gene results in multiple

hematopoietic abnormalities. EMBO J 15:5647-5658.

Meyer RA,Jr, Henley CM, Meyer MH, Morgan PL, McDonald AG, Mills C, Price DK (1998) Partial

deletion of both the spermine synthase gene and the Pex gene in the X-linked hypophosphatemic,

gyro (Gy) mouse. Genomics 48:289-295.

Morrison SJ, Weissman IL (1994) The long-term repopulating subset of hematopoietic stem cells is

deterministic and isolatable by phenotype. Immunity 1:661-673.

Murakami Y, Ichiba T, Matsufuji S, Hayashi S (1996) Cloning of antizyme inhibitor, a highly

homologous protein to ornithine decarboxylase. J Biol Chem 271:3340-3342.

Murray-Stewart T, Wang Y, Goodwin A, Hacker A, Meeker A, Casero RA,Jr (2008) Nuclear

localization of human spermine oxidase isoforms - possible implications in drug response and

disease etiology. FEBS J 275:2795-2806.

Nakashima K, Zhou X, Kunkel G, Zhang Z, Deng JM, Behringer RR, de Crombrugghe B (2002) The

novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and

bone formation. Cell 108:17-29.

Nakorn TN, Miyamoto T, Weissman IL (2003) Characterization of mouse clonogenic

megakaryocyte progenitors. Proc Natl Acad Sci U S A 100:205-210.

Naveiras O, Nardi V, Wenzel PL, Hauschka PV, Fahey F, Daley GQ (2009) Bone-marrow

adipocytes as negative regulators of the haematopoietic microenvironment. Nature 460:259-263.

50

Nerlov C, Querfurth E, Kulessa H, Graf T (2000) GATA-1 interacts with the myeloid PU.1

transcription factor and represses PU.1-dependent transcription. Blood 95:2543-2551.

Neve A, Corrado A, Cantatore FP (2013) Osteocalcin: skeletal and extra-skeletal effects. J Cell

Physiol 228:1149-1153.

Newton GL, Aguilera JA, Ward JF, Fahey RC (1996) Polyamine-induced compaction and

aggregation of DNA--a major factor in radioprotection of chromatin under physiological conditions.

Radiat Res 145:776-780.

Niiranen K, Keinanen TA, Pirinen E, Heikkinen S, Tusa M, Fatrai S, Suppola S, Pietila M, Uimari

A, Laakso M, Alhonen L, Janne J (2006) Mice with targeted disruption of spermidine/spermine N1-

acetyltransferase gene maintain nearly normal tissue polyamine homeostasis but show signs of

insulin resistance upon aging. J Cell Mol Med 10:933-945.

Nishimura K, Nakatsu F, Kashiwagi K, Ohno H, Saito T, Igarashi K (2002) Essential role of S-

adenosylmethionine decarboxylase in mouse embryonic development. Genes Cells 7:41-47.

Nissinen AE, Laitinen LM, Kakko S, Helander A, Savolainen MJ, Horkko S (2012) Low plasma

antibodies specific for phosphatidylethanol in alcohol abusers and patients with alcoholic

pancreatitis. Addict Biol 17:1057-1067.

Oredsson SM (2003) Polyamine dependence of normal cell-cycle progression. Biochem Soc Trans

31:366-370.

Orimo H (2010) The mechanism of mineralization and the role of alkaline phosphatase in health and

disease. J Nippon Med Sch 77:4-12.

Osawa M, Hanada K, Hamada H, Nakauchi H (1996) Long-term lymphohematopoietic

reconstitution by a single CD34-low/negative hematopoietic stem cell. Science 273:242-245.

Owusu-Ansah E, Banerjee U (2009) Reactive oxygen species prime Drosophila haematopoietic

progenitors for differentiation. Nature 461:537-541.

Park MH, Cooper HL, Folk JE (1981) Identification of hypusine, an unusual amino acid, in a protein

from human lymphocytes and of spermidine as its biosynthetic precursor. Proc Natl Acad Sci U S A

78:2869-2873.

Pegg AE, Michael AJ (2010) Spermine synthase. Cell Mol Life Sci 67:113-121.

Pegg AE (2009) S-Adenosylmethionine decarboxylase. Essays Biochem 46:25-45.

Pegg AE (2008) Spermidine/spermine-N(1)-acetyltransferase: a key metabolic regulator. Am J

Physiol Endocrinol Metab 294:E995-1010.

Pegg AE, Xiong H, Feith DJ, Shantz LM (1998) S-adenosylmethionine decarboxylase: structure,

function and regulation by polyamines. Biochem Soc Trans 26:580-586.

Pendeville H, Carpino N, Marine JC, Takahashi Y, Muller M, Martial JA, Cleveland JL (2001) The

ornithine decarboxylase gene is essential for cell survival during early murine development. Mol Cell

Biol 21:6549-6558.

Persson L (2009) Polyamine homoeostasis. Essays Biochem 46:11-24.

51

Persson L, Pegg AE (1984) Studies of the induction of spermidine/spermine N1-acetyltransferase

using a specific antiserum. J Biol Chem 259:12364-12367.

Pietila M, Pirinen E, Keskitalo S, Juutinen S, Pasonen-Seppanen S, Keinanen T, Alhonen L, Janne J

(2005) Disturbed keratinocyte differentiation in transgenic mice and organotypic keratinocyte

cultures as a result of spermidine/spermine N-acetyltransferase overexpression. J Invest Dermatol

124:596-601.

Pietila M, Parkkinen JJ, Alhonen L, Janne J (2001) Relation of skin polyamines to the hairless

phenotype in transgenic mice overexpressing spermidine/spermine N-acetyltransferase. J Invest

Dermatol 116:801-805.

Pietila M, Alhonen L, Halmekyto M, Kanter P, Janne J, Porter CW (1997) Activation of polyamine

catabolism profoundly alters tissue polyamine pools and affects hair growth and female fertility in

transgenic mice overexpressing spermidine/spermine N1-acetyltransferase. J Biol Chem 272:18746-

18751.

Pinsky MR (2004) Dysregulation of the immune response in severe sepsis. Am J Med Sci 328:220-

229.

Pirinen E, Gylling H, Itkonen P, Yaluri N, Heikkinen S, Pietila M, Kuulasmaa T, Tusa M, Cerrada-

Gimenez M, Pihlajamaki J, Alhonen L, Janne J, Miettinen TA, Laakso M (2010) Activated

polyamine catabolism leads to low cholesterol levels by enhancing bile acid synthesis. Amino Acids

38:549-560.

Pirinen E, Kuulasmaa T, Pietila M, Heikkinen S, Tusa M, Itkonen P, Boman S, Skommer J,

Virkamaki A, Hohtola E, Kettunen M, Fatrai S, Kansanen E, Koota S, Niiranen K, Parkkinen J,

Levonen AL, Yla-Herttuala S, Hiltunen JK, Alhonen L, Smith U, Janne J, Laakso M (2007)

Enhanced polyamine catabolism alters homeostatic control of white adipose tissue mass, energy

expenditure, and glucose metabolism. Mol Cell Biol 27:4953-4967.

Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti

DW, Craig S, Marshak DR (1999) Multilineage potential of adult human mesenchymal stem cells.

Science 284:143-147.

Plass C, Oakes C, Blum W, Marcucci G (2008) Epigenetics in acute myeloid leukemia. Semin Oncol

35:378-387.

Pollmann D, Siepmann S, Geppert R, Wernecke KD, Possinger K, Luftner D (2007) The amino-

terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and

extent of metastatic spread in osseous metastatic breast cancer. Anticancer Res 27:1853-1862.

Raaijmakers MH, Mukherjee S, Guo S, Zhang S, Kobayashi T, Schoonmaker JA, Ebert BL, Al-

Shahrour F, Hasserjian RP, Scadden EO, Aung Z, Matza M, Merkenschlager M, Lin C, Rommens

JM, Scadden DT (2010) Bone progenitor dysfunction induces myelodysplasia and secondary

leukaemia. Nature 464:852-857.

Radulovic V, de Haan G, Klauke K (2013) Polycomb-group proteins in hematopoietic stem cell

regulation and hematopoietic neoplasms. Leukemia 27:523-533.

Randall TD, Lund FE, Howard MC, Weissman IL (1996) Expression of murine CD38 defines a

population of long-term reconstituting hematopoietic stem cells. Blood 87:4057-4067.

52

Rekhtman N, Choe KS, Matushansky I, Murray S, Stopka T, Skoultchi AI (2003) PU.1 and pRB

interact and cooperate to repress GATA-1 and block erythroid differentiation. Mol Cell Biol

23:7460-7474.

Reddy BS, Watanabe K, Weisburger JH, Wynder EL (1977) Promoting effect of bile acids in colon

carcinogenesis in germ-free and conventional F344 rats. Cancer Res 37:3238-3242.

Rissanen JP, Suominen MI, Peng Z, Morko J, Rasi S, Risteli J, Halleen JM (2008) Short-term

changes in serum PINP predict long-term changes in trabecular bone in the rat ovariectomy model.

Calcif Tissue Int 82:155-161.

Ross EA, Douglas MR, Wong SH, Ross EJ, Curnow SJ, Nash GB, Rainger E, Scheel-Toellner D,

Lord JM, Salmon M, Buckley CD (2006) Interaction between integrin alpha9beta1 and vascular cell

adhesion molecule-1 (VCAM-1) inhibits neutrophil apoptosis. Blood 107:1178-1183.

Rossi DJ, Bryder D, Zahn JM, Ahlenius H, Sonu R, Wagers AJ, Weissman IL (2005) Cell intrinsic

alterations underlie hematopoietic stem cell aging. Proc Natl Acad Sci U S A 102:9194-9199.

Sakata K, Kashiwagi K, Igarashi K (2000) Properties of a polyamine transporter regulated by

antizyme. Biochem J 347 Pt 1:297-303.

Sallmyr A, Fan J, Rassool FV (2008) Genomic instability in myeloid malignancies: increased

reactive oxygen species (ROS), DNA double strand breaks (DSBs) and error-prone repair. Cancer

Lett 270:1-9.

Sardina JL, Lopez-Ruano G, Sanchez-Abarca LI, Perez-Simon JA, Gaztelumendi A, Trigueros C,

Llanillo M, Sanchez-Yague J, Hernandez-Hernandez A (2010) p22phox-dependent NADPH oxidase

activity is required for megakaryocytic differentiation. Cell Death Differ 17:1842-1854.

Schipper RG, Penning LC, Verhofstad AA (2000) Involvement of polyamines in apoptosis. Facts

and controversies: effectors or protectors?. Semin Cancer Biol 10:55-68.

Scholz B, Marschalek R (2012) Epigenetics and blood disorders. Br J Haematol 158:307-322.

Scott EW, Simon MC, Anastasi J, Singh H (1994) Requirement of transcription factor PU.1 in the

development of multiple hematopoietic lineages. Science 265:1573-1577.

Seiler N, Delcros JG, Moulinoux JP (1996) Polyamine transport in mammalian cells. An update. Int J

Biochem Cell Biol 28:843-861.

Seiler N, Graham A, Bartholeyns J (1981) Enhanced urinary excretion of N1-acetylspermidine and

the presence of tumors. Cancer Res 41:1572-1573.

Sodek J, Ganss B, McKee MD (2000) Osteopontin. Crit Rev Oral Biol Med 11:279-303.

Soulet D, Covassin L, Kaouass M, Charest-Gaudreault R, Audette M, Poulin R (2002) Role of

endocytosis in the internalization of spermidine-C(2)-BODIPY, a highly fluorescent probe of

polyamine transport. Biochem J 367:347-357.

Stein GS, Lian JB, van Wijnen AJ, Stein JL, Montecino M, Javed A, Zaidi SK, Young DW, Choi JY,

Pockwinse SM (2004) Runx2 control of organization, assembly and activity of the regulatory

machinery for skeletal gene expression. Oncogene 23:4315-4329.

53

TABOR H (1962) The protective effect of spermine and other polyamines against heat denaturation

of deoxyribonucleic acid. Biochemistry 1:496-501.

Thomas TJ, Messner RP (1986) A left-handed (Z) conformation of poly(dA-dC).poly(dG-dT)

induced by polyamines. Nucleic Acids Res 14:6721-6733.

Tjabringa GS, Zandieh-Doulabi B, Helder MN, Knippenberg M, Wuisman PI, Klein-Nulend J (2008)

The polymine spermine regulates osteogenic differentiation in adipose stem cells. J Cell Mol Med

12:1710-1717.

Tome ME, Fiser SM, Payne CM, Gerner EW (1997) Excess putrescine accumulation inhibits the

formation of modified eukaryotic initiation factor 5A (eIF-5A) and induces apoptosis. Biochem J 328

( Pt 3):847-854.

Tomitori H, Usui T, Saeki N, Ueda S, Kase H, Nishimura K, Kashiwagi K, Igarashi K (2005)

Polyamine oxidase and acrolein as novel biochemical markers for diagnosis of cerebral stroke.

Stroke 36:2609-2613.

Tothova Z, Kollipara R, Huntly BJ, Lee BH, Castrillon DH, Cullen DE, McDowell EP, Lazo-

Kallanian S, Williams IR, Sears C, Armstrong SA, Passegue E, DePinho RA, Gilliland DG (2007)

FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress.

Cell 128:325-339.

Traver D, Miyamoto T, Christensen J, Iwasaki-Arai J, Akashi K, Weissman IL (2001) Fetal liver

myelopoiesis occurs through distinct, prospectively isolatable progenitor subsets. Blood 98:627-635.

Tripathi AK, Chaturvedi R, Ahmad R, Asim M, Sawlani KK, Singh RL, Tekwani BL (2002)

Peripheral blood leucocytes ornithine decarboxylase activity in chronic myeloid leukemia patients:

prognostic and therapeutic implications. Leuk Res 26:349-354.

Tucker JM, Murphy JT, Kisiel N, Diegelman P, Barbour KW, Davis C, Medda M, Alhonen L, Janne

J, Kramer DL, Porter CW, Berger FG (2005) Potent modulation of intestinal tumorigenesis in

Apcmin/+ mice by the polyamine catabolic enzyme spermidine/spermine N1-acetyltransferase.

Cancer Res 65:5390-5398.

Udagawa N, Takahashi N, Akatsu T, Tanaka H, Sasaki T, Nishihara T, Koga T, Martin TJ, Suda T

(1990) Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into

osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc

Natl Acad Sci U S A 87:7260-7264.

Uimari A, Keinanen TA, Karppinen A, Woster P, Uimari P, Janne J, Alhonen L (2009) Spermine

analogue-regulated expression of spermidine/spermine N1-acetyltransferase and its effects on

depletion of intracellular polyamine pools in mouse fetal fibroblasts. Biochem J 422:101-109.

Vaananen HK, Horton M (1995) The osteoclast clear zone is a specialized cell-extracellular matrix

adhesion structure. J Cell Sci 108 ( Pt 8):2729-2732.

van Bezooijen RL, Roelen BA, Visser A, van der Wee-Pals L, de Wilt E, Karperien M, Hamersma

H, Papapoulos SE, ten Dijke P, Lowik CW (2004) Sclerostin is an osteocyte-expressed negative

regulator of bone formation, but not a classical BMP antagonist. J Exp Med 199:805-814.

Venezia TA, Merchant AA, Ramos CA, Whitehouse NL, Young AS, Shaw CA, Goodell MA (2004)

Molecular signatures of proliferation and quiescence in hematopoietic stem cells. PLoS Biol 2:e301.

54

Vicente C, Conchillo A, Garcia-Sanchez MA, Odero MD (2012) The role of the GATA2

transcription factor in normal and malignant hematopoiesis. Crit Rev Oncol Hematol 82:1-17.

Visnjic D, Kalajzic Z, Rowe DW, Katavic V, Lorenzo J, Aguila HL (2004) Hematopoiesis is

severely altered in mice with an induced osteoblast deficiency. Blood 103:3258-3264.

Vujcic S, Liang P, Diegelman P, Kramer DL, Porter CW (2003) Genomic identification and

biochemical characterization of the mammalian polyamine oxidase involved in polyamine back-

conversion. Biochem J 370:19-28.

Vujcic S, Diegelman P, Bacchi CJ, Kramer DL, Porter CW (2002) Identification and characterization

of a novel flavin-containing spermine oxidase of mammalian cell origin. Biochem J 367:665-675.

Vujcic S, Halmekyto M, Diegelman P, Gan G, Kramer DL, Janne J, Porter CW (2000) Effects of

conditional overexpression of spermidine/spermine N1-acetyltransferase on polyamine pool

dynamics, cell growth, and sensitivity to polyamine analogs. J Biol Chem 275:38319-38328.

Vuohelainen S, Pirinen E, Cerrada-Gimenez M, Keinanen TA, Uimari A, Pietila M, Khomutov AR,

Janne J, Alhonen L (2010) Spermidine is indispensable in differentiation of 3T3-L1 fibroblasts to

adipocytes. J Cell Mol Med 14:1683-1692.

Walker DG (1975) Control of bone resorption by hematopoietic tissue. The induction and reversal of

congenital osteopetrosis in mice through use of bone marrow and splenic transplants. J Exp Med

142:651-663.

Walkley CR, Olsen GH, Dworkin S, Fabb SA, Swann J, McArthur GA, Westmoreland SV,

Chambon P, Scadden DT, Purton LE (2007) A microenvironment-induced myeloproliferative

syndrome caused by retinoic acid receptor gamma deficiency. Cell 129:1097-1110.

Wallace HM (2009) The polyamines: past, present and future. Essays Biochem 46:1-9.

Wallace HM, Fraser AV, Hughes A (2003) A perspective of polyamine metabolism. Biochem J

376:1-14.

Wallace HM, Duthie J, Evans DM, Lamond S, Nicoll KM, Heys SD (2000) Alterations in polyamine

catabolic enzymes in human breast cancer tissue. Clin Cancer Res 6:3657-3661.

Wang X, Ikeguchi Y, McCloskey DE, Nelson P, Pegg AE (2004) Spermine synthesis is required for

normal viability, growth, and fertility in the mouse. J Biol Chem 279:51370-51375.

Wang Y, Gong B, Dai W, Lu L (1998) Identification of immediate early genes during TPA-induced

human myeloblastic leukemia ML-1 cell differentiation. Gene 216:293-302.

Watanabe S, Kusama-Eguchi K, Kobayashi H, Igarashi K (1991) Estimation of polyamine binding to

macromolecules and ATP in bovine lymphocytes and rat liver. J Biol Chem 266:20803-20809.

Williams K (1997) Interactions of polyamines with ion channels. Biochem J 325 ( Pt 2):289-297.

Woolthuis CM, de Haan G, Huls G (2011) Aging of hematopoietic stem cells: Intrinsic changes or

micro-environmental effects?. Curr Opin Immunol 23:512-517.

Wu H, Min J, Zeng H, McCloskey DE, Ikeguchi Y, Loppnau P, Michael AJ, Pegg AE, Plotnikov AN

(2008) Crystal structure of human spermine synthase: implications of substrate binding and catalytic

mechanism. J Biol Chem 283:16135-16146.

55

Wu H, Min J, Ikeguchi Y, Zeng H, Dong A, Loppnau P, Pegg AE, Plotnikov AN (2007) Structure

and mechanism of spermidine synthases. Biochemistry 46:8331-8339.

Xiao L, Celano P, Mank AR, Griffin C, Jabs EW, Hawkins AL, Casero RA,Jr (1992) Structure of the

human spermidine/spermine N1-acetyltransferase gene (exon/intron gene organization and

localization to Xp22.1). Biochem Biophys Res Commun 187:1493-1502.

Xiong J, O'Brien CA (2012) Osteocyte RANKL: new insights into the control of bone remodeling. J

Bone Miner Res 27:499-505.

Yamamoto T, Hinoi E, Fujita H, Iezaki T, Takahata Y, Takamori M, Yoneda Y (2012) The natural

polyamines spermidine and spermine prevent bone loss through preferential disruption of

osteoclastic activation in ovariectomized mice. Br J Pharmacol 166:1084-1096.

Yamazaki S, Ema H, Karlsson G, Yamaguchi T, Miyoshi H, Shioda S, Taketo MM, Karlsson S,

Iwama A, Nakauchi H (2011) Nonmyelinating Schwann cells maintain hematopoietic stem cell

hibernation in the bone marrow niche. Cell 147:1146-1158.

Zahedi K, Barone S, Kramer DL, Amlal H, Alhonen L, Janne J, Porter CW, Soleimani M (2010) The

role of spermidine/spermine N1-acetyltransferase in endotoxin-induced acute kidney injury. Am J

Physiol Cell Physiol 299:C164-74.

Zhang DE, Zhang P, Wang ND, Hetherington CJ, Darlington GJ, Tenen DG (1997a) Absence of

granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer

binding protein alpha-deficient mice. Proc Natl Acad Sci U S A 94:569-574.

Zhang J, Niu C, Ye L, Huang H, He X, Tong WG, Ross J, Haug J, Johnson T, Feng JQ, Harris S,

Wiedemann LM, Mishina Y, Li L (2003) Identification of the haematopoietic stem cell niche and

control of the niche size. Nature 425:836-841.

Zhang M, Caragine T, Wang H, Cohen PS, Botchkina G, Soda K, Bianchi M, Ulrich P, Cerami A,

Sherry B, Tracey KJ (1997b) Spermine inhibits proinflammatory cytokine synthesis in human

mononuclear cells: a counterregulatory mechanism that restrains the immune response. J Exp Med

185:1759-1768.

Zhang P, Behre G, Pan J, Iwama A, Wara-Aswapati N, Radomska HS, Auron PE, Tenen DG, Sun Z

(1999) Negative cross-talk between hematopoietic regulators: GATA proteins repress PU.1. Proc

Natl Acad Sci USA 96:8705-8710.

Zhang P, Iwasaki-Arai J, Iwasaki H, Fenyus ML, Dayaram T, Owens BM, Shigematsu H, Levantini

E, Huettner CS, Lekstrom-Himes JA, Akashi K, Tenen DG (2004) Enhancement of hematopoietic

stem cell repopulating capacity and self-renewal in the absence of the transcription factor C/EBP

alpha. Immunity 21:853-863.

Zhao Q, Wang X, Liu Y, He A, Jia R (2010) NFATc1: functions in osteoclasts. Int J Biochem Cell

Biol 42:576-579.

Zhu S, Ashok M, Li J, Li W, Yang H, Wang P, Tracey KJ, Sama AE, Wang H (2009) Spermine

protects mice against lethal sepsis partly by attenuating surrogate inflammatory markers. Mol Med

15:275-282.

Publications of the University of Eastern Finland

Dissertations in Health Sciences

isbn 978-952-61-1321-0

Publications of the University of Eastern FinlandDissertations in Health Sciences

Polyamines are ubiquitious

molecules essential for cell

proliferation. However, the

role of polyamine metabolism

in the immune response,

hematopoiesis, and bone

remodeling is largely unknown

and was thus addressed in this

study. The study showed that

enhanced activity of spermidine/

spermine N1-acetyltransferase

(SSAT), a catabolic regulator of

polyamines, was associated with

disturbed hematopoiesis and bone

remodeling in mice and myeloid

leukemias in humans.

dissertatio

ns | 207 | S

ini P

irn

es-Ka

rh

u | Sperm

idine/spermine N

1-acetyltransferase in Mouse H

ematopoiesis and B

one Rem

odeling...

Sini Pirnes-KarhuSpermidine/spermine

N1-acetyltransferase in Mouse Hematopoiesis

and Bone Remodeling and in Human Leukemias

Sini Pirnes-Karhu

Spermidine/spermine N1-acetyltransferase in Mouse Hematopoiesis and Bone Remodeling and in Human Leukemias